

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Emerging novel agents for patients with advanced... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-493/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-493" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Childrenâ€™s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force" />
    
            <meta name="og:title" content="F1000Research Article: Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children&rsquo;s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force.">
            <meta name="og:description" content="Read the latest article version by Kelly Bailey, Carrye Cost, Ian Davis, Julia Glade-Bender, Patrick Grohar, Peter Houghton, Michael Isakoff, Elizabeth Stewart, Nadia Laack, Jason Yustein, Damon Reed, Katherine Janeway, Richard Gorlick, Stephen Lessnick, Steven DuBois, Pooja Hingorani, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="19837">
            <meta name="article-id" content="18139">
            <meta name="dc.title" content="Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children&rsquo;s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force">
            <meta name="dc.description" content="Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children&rsquo;s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group&rsquo;s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.">
            <meta name="dc.subject" content="Ewing sarcoma, metastasis, relapse, clinical trials, therapy">
            <meta name="dc.creator" content="Bailey, Kelly">
            <meta name="dc.creator" content="Cost, Carrye">
            <meta name="dc.creator" content="Davis, Ian">
            <meta name="dc.creator" content="Glade-Bender, Julia">
            <meta name="dc.creator" content="Grohar, Patrick">
            <meta name="dc.creator" content="Houghton, Peter">
            <meta name="dc.creator" content="Isakoff, Michael">
            <meta name="dc.creator" content="Stewart, Elizabeth">
            <meta name="dc.creator" content="Laack, Nadia">
            <meta name="dc.creator" content="Yustein, Jason">
            <meta name="dc.creator" content="Reed, Damon">
            <meta name="dc.creator" content="Janeway, Katherine">
            <meta name="dc.creator" content="Gorlick, Richard">
            <meta name="dc.creator" content="Lessnick, Stephen">
            <meta name="dc.creator" content="DuBois, Steven">
            <meta name="dc.creator" content="Hingorani, Pooja">
            <meta name="dc.date" content="2019/04/15">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.18139.1">
            <meta name="dc.source" content="F1000Research 2019 8:493">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Ewing sarcoma">
            <meta name="prism.keyword" content="metastasis">
            <meta name="prism.keyword" content="relapse">
            <meta name="prism.keyword" content="clinical trials">
            <meta name="prism.keyword" content="therapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/04/15">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="493">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.18139.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-493">
            <meta name="citation_title" content="Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children&rsquo;s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force">
            <meta name="citation_abstract" content="Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children&rsquo;s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group&rsquo;s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.">
            <meta name="citation_description" content="Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children&rsquo;s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group&rsquo;s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.">
            <meta name="citation_keywords" content="Ewing sarcoma, metastasis, relapse, clinical trials, therapy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Kelly Bailey">
            <meta name="citation_author_institution" content="Division of Pediatric Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA">
            <meta name="citation_author" content="Carrye Cost">
            <meta name="citation_author_institution" content="Center for Cancer and Blood Disorders, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA">
            <meta name="citation_author" content="Ian Davis">
            <meta name="citation_author_institution" content="Departments of Pediatrics and Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA">
            <meta name="citation_author" content="Julia Glade-Bender">
            <meta name="citation_author_institution" content="Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA">
            <meta name="citation_author" content="Patrick Grohar">
            <meta name="citation_author_institution" content="Departement of Pediatrics, Van Andel Institute, Helen De Vos Children&rsquo;s Hospital and Michigan State University, Grand Rapids, MI, USA">
            <meta name="citation_author" content="Peter Houghton">
            <meta name="citation_author_institution" content="Greehey Children&rsquo;s Cancer Research Institute, University of Texas Health Science Center, San Antonio, TX, USA">
            <meta name="citation_author" content="Michael Isakoff">
            <meta name="citation_author_institution" content="Center for Cancer and Blood Disorders, Connecticut Children&rsquo;s Medical Center, Hartford, CT, USA">
            <meta name="citation_author" content="Elizabeth Stewart">
            <meta name="citation_author_institution" content="Department of Oncology, St. Jude Children&rsquo;s Research Hospital, Memphis, TN, USA">
            <meta name="citation_author" content="Nadia Laack">
            <meta name="citation_author_institution" content="Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA">
            <meta name="citation_author" content="Jason Yustein">
            <meta name="citation_author_institution" content="The Faris D. Virani Ewing Sarcoma Center at the Texas Children&rsquo;s Cancer Center, Baylor College of Medicine, Houston, TX, USA">
            <meta name="citation_author" content="Damon Reed">
            <meta name="citation_author_institution" content="AYA Program, Moffitt Cancer Center, Tampa, FL, USA">
            <meta name="citation_author_institution" content="Johns Hopkins All Children&rsquo;s Hospital, St. Petersburg, FL, USA">
            <meta name="citation_author" content="Katherine Janeway">
            <meta name="citation_author_institution" content="Dana-Farber/Boston Children&rsquo;s Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA">
            <meta name="citation_author" content="Richard Gorlick">
            <meta name="citation_author_institution" content="Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA">
            <meta name="citation_author" content="Stephen Lessnick">
            <meta name="citation_author_institution" content="Center for Childhood Cancer and Blood Diseases, Research Institute at Nationwide Children&rsquo;s Hospital, Columbus, OH, USA">
            <meta name="citation_author_institution" content="Division of Pediatric Hematology/Oncology/Bone Marrow Transplantation, The Ohio State University College of Medicine, Columbus, OH, USA">
            <meta name="citation_author" content="Steven DuBois">
            <meta name="citation_author_institution" content="Dana-Farber/Boston Children&rsquo;s Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA">
            <meta name="citation_author" content="Pooja Hingorani">
            <meta name="citation_author_institution" content="Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA">
            <meta name="citation_publication_date" content="2019/04/15">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="493">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.18139.1">
            <meta name="citation_firstpage" content="493">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-493/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-493.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=19837 /> <input type=hidden id=articleId name=articleId value=18139 /> <input type=hidden id=xmlUrl value="/articles/8-493/v1/xml"/> <input type=hidden id=xmlFileName value="-8-493-v1.xml"> <input type=hidden id=article_uuid value=42f39dc6-b0de-4551-bddc-eb93b2f7dd29 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Childrenâ€™s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.18139.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.18139.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-493"
  },
  "headline": "Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Childrenâ€™s Oncology...",
  "datePublished": "2019-04-15T12:09:06",
  "dateModified": "2019-04-15T12:09:06",
  "author": [
    {
      "@type": "Person",
      "name": "Kelly Bailey"
    },    {
      "@type": "Person",
      "name": "Carrye Cost"
    },    {
      "@type": "Person",
      "name": "Ian Davis"
    },    {
      "@type": "Person",
      "name": "Julia Glade-Bender"
    },    {
      "@type": "Person",
      "name": "Patrick Grohar"
    },    {
      "@type": "Person",
      "name": "Peter Houghton"
    },    {
      "@type": "Person",
      "name": "Michael Isakoff"
    },    {
      "@type": "Person",
      "name": "Elizabeth Stewart"
    },    {
      "@type": "Person",
      "name": "Nadia Laack"
    },    {
      "@type": "Person",
      "name": "Jason Yustein"
    },    {
      "@type": "Person",
      "name": "Damon Reed"
    },    {
      "@type": "Person",
      "name": "Katherine Janeway"
    },    {
      "@type": "Person",
      "name": "Richard Gorlick"
    },    {
      "@type": "Person",
      "name": "Stephen Lessnick"
    },    {
      "@type": "Person",
      "name": "Steven DuBois"
    },    {
      "@type": "Person",
      "name": "Pooja Hingorani"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children&rsquo;s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group&rsquo;s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-493/v1",
            "name": "Emerging novel agents for patients with advanced Ewing sarcoma: a..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Emerging novel agents for patients with advanced Ewing sarcoma: a... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=19837 data-id=18139 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18139.1" data-recommended="" data-doi="10.12688/f1000research.18139.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-493/v1/pdf?article_uuid=42f39dc6-b0de-4551-bddc-eb93b2f7dd29" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-18139-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-18139-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-18139-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Bailey K, Cost C, Davis I <em>et al.</em> Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Childrenâ€™s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):493 (<a class=new-orange href="https://doi.org/10.12688/f1000research.18139.1" target=_blank>https://doi.org/10.12688/f1000research.18139.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-18139-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=18139 id=track-article-signin-18139 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18139?target=/articles/8-493/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=19837 /> <input name=articleId type=hidden value=18139 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Childrenâ€™s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Kelly Bailey<a href="https://orcid.org/0000-0003-3925-3243" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3925-3243</div><sup>1</sup><sup>*</sup>,&nbsp;</span><span class="">Carrye Cost<sup>2</sup><sup>*</sup>,&nbsp;</span><span class="">Ian Davis<sup>3</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Julia Glade-Bender<sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Patrick Grohar<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Peter Houghton<sup>6</sup>,&nbsp;</span><span class=article-page-hidden-authors>Michael Isakoff<sup>7</sup>,&nbsp;</span><span class=article-page-hidden-authors>Elizabeth Stewart<sup>8</sup>,&nbsp;</span><span class=article-page-hidden-authors>Nadia Laack<sup>9</sup>,&nbsp;</span><span class=article-page-hidden-authors>Jason Yustein<sup>10</sup>,&nbsp;</span><span class=article-page-hidden-authors>Damon Reed<sup>11,12</sup>,&nbsp;</span><span class=article-page-hidden-authors>Katherine Janeway<sup>13</sup>,&nbsp;</span><span class=article-page-hidden-authors>Richard Gorlick<sup>14</sup>,&nbsp;</span><span class="">Stephen Lessnick<sup>15,16</sup><sup>*</sup>,&nbsp;</span><span class="">Steven DuBois<sup>13</sup><sup>*</sup>,&nbsp;</span><span class=""><a href="mailto:phingorani@phoenixchildrens.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Pooja Hingorani</span></a><sup>17</sup><sup>*</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Kelly Bailey<a href="http://orcid.org/0000-0003-3925-3243" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3925-3243</div><sup>1</sup><sup>*</sup>,&nbsp;</span><span class="">Carrye Cost<sup>2</sup><sup>*</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Ian Davis<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Julia Glade-Bender<sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Patrick Grohar<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Peter Houghton<sup>6</sup>,&nbsp;</span><span class=article-page-hidden-authors>Michael Isakoff<sup>7</sup>,&nbsp;</span><span class=article-page-hidden-authors>Elizabeth Stewart<sup>8</sup>,&nbsp;</span><span class=article-page-hidden-authors>Nadia Laack<sup>9</sup>,&nbsp;</span><span class=article-page-hidden-authors>Jason Yustein<sup>10</sup>,&nbsp;</span><span class=article-page-hidden-authors>Damon Reed<sup>11,12</sup>,&nbsp;</span><span class=article-page-hidden-authors>Katherine Janeway<sup>13</sup>,&nbsp;</span><span class=article-page-hidden-authors>Richard Gorlick<sup>14</sup>,&nbsp;</span><span class=article-page-hidden-authors>Stephen Lessnick<sup>15,16</sup><sup>*</sup>,&nbsp;</span><span class="">Steven DuBois<sup>13</sup><sup>*</sup>,&nbsp;</span><span class=""><a href="mailto:phingorani@phoenixchildrens.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Pooja Hingorani</span></a><sup>17</sup><sup>*</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class="authors extra-info"> <sup>*</sup> Equal contributors </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 15 Apr 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.18139.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Pediatric Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA<br/> <sup>2</sup> Center for Cancer and Blood Disorders, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA<br/> <sup>3</sup> Departments of Pediatrics and Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA<br/> <sup>4</sup> Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA<br/> <sup>5</sup> Departement of Pediatrics, Van Andel Institute, Helen De Vos Children&rsquo;s Hospital and Michigan State University, Grand Rapids, MI, USA<br/> <sup>6</sup> Greehey Children&rsquo;s Cancer Research Institute, University of Texas Health Science Center, San Antonio, TX, USA<br/> <sup>7</sup> Center for Cancer and Blood Disorders, Connecticut Children&rsquo;s Medical Center, Hartford, CT, USA<br/> <sup>8</sup> Department of Oncology, St. Jude Children&rsquo;s Research Hospital, Memphis, TN, USA<br/> <sup>9</sup> Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA<br/> <sup>10</sup> The Faris D. Virani Ewing Sarcoma Center at the Texas Children&rsquo;s Cancer Center, Baylor College of Medicine, Houston, TX, USA<br/> <sup>11</sup> AYA Program, Moffitt Cancer Center, Tampa, FL, USA<br/> <sup>12</sup> Johns Hopkins All Children&rsquo;s Hospital, St. Petersburg, FL, USA<br/> <sup>13</sup> Dana-Farber/Boston Children&rsquo;s Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA<br/> <sup>14</sup> Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <sup>15</sup> Center for Childhood Cancer and Blood Diseases, Research Institute at Nationwide Children&rsquo;s Hospital, Columbus, OH, USA<br/> <sup>16</sup> Division of Pediatric Hematology/Oncology/Bone Marrow Transplantation, The Ohio State University College of Medicine, Columbus, OH, USA<br/> <sup>17</sup> Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA<br/> <p> <div class=margin-bottom> Kelly Bailey <br/> <span>Roles: </span> Conceptualization, Methodology, Visualization, Writing â€“ Original Draft Preparation, Writing â€“ Review & Editing </div> <div class=margin-bottom> Carrye Cost <br/> <span>Roles: </span> Conceptualization, Methodology, Visualization, Writing â€“ Original Draft Preparation, Writing â€“ Review & Editing </div> <div class=margin-bottom> Ian Davis <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Julia Glade-Bender <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Patrick Grohar <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Peter Houghton <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Michael Isakoff <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Elizabeth Stewart <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Nadia Laack <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Jason Yustein <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Damon Reed <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Katherine Janeway <br/> <span>Roles: </span> Writing â€“ Review & Editing </div> <div class=margin-bottom> Richard Gorlick <br/> <span>Roles: </span> Writing â€“ Review & Editing </div> <div class=margin-bottom> Stephen Lessnick <br/> <span>Roles: </span> Methodology, Project Administration, Supervision, Writing â€“ Review & Editing </div> <div class=margin-bottom> Steven DuBois <br/> <span>Roles: </span> Conceptualization, Methodology, Project Administration, Supervision, Visualization, Writing â€“ Review & Editing </div> <div class=margin-bottom> Pooja Hingorani <br/> <span>Roles: </span> Conceptualization, Methodology, Project Administration, Supervision, Visualization, Writing â€“ Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=49238-47019></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=49236-47021></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=49237-47020></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Childrenâ€™s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This groupâ€™s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Ewing sarcoma, metastasis, relapse, clinical trials, therapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Pooja Hingorani (<a href="mailto:phingorani@phoenixchildrens.com">phingorani@phoenixchildrens.com</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Pooja Hingorani </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work is supported by the Childrenâ€™s Oncology Group and the National Cancer Institute of the National Institutes of Health under NCTN Operations Center Grant U10CA180886. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; Â© 2019 Bailey K <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Bailey K, Cost C, Davis I <em>et al.</em> Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Childrenâ€™s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):493 (<a href="https://doi.org/10.12688/f1000research.18139.1" target=_blank>https://doi.org/10.12688/f1000research.18139.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 15 Apr 2019, <b>8</b>(F1000 Faculty Rev):493 (<a href="https://doi.org/10.12688/f1000research.18139.1" target=_blank>https://doi.org/10.12688/f1000research.18139.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 15 Apr 2019, <b>8</b>(F1000 Faculty Rev):493 (<a href="https://doi.org/10.12688/f1000research.18139.1" target=_blank>https://doi.org/10.12688/f1000research.18139.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d1627e505>Introduction</h2><p class="" id=d1627e508>Ewing sarcoma (ES) is a small round blue cell bone tumor most commonly occurring in adolescent and young adult (AYA) patients. ES is a classic fusion oncoprotein-driven tumor typically associated with a reciprocal translocation involving <i>EWSR1</i> (chromosome 22) and the ETS family transcription factor <i>FLI1</i> (chromosome 11)<sup><a href="#ref-1">1</a></sup>. These fusions may arise from chromoplexy events<sup><a href="#ref-2">2</a></sup>. Whereas classically no known genetic predisposition syndromes were linked to ES tumor development, recent evidence suggests that germline mutations in genes regulating DNA damage pathways are associated with an increased risk of developing ES<sup><a href="#ref-3">3</a></sup>. The field continues to learn more about the origins, nature, and behavior of the EWS-FLI1 oncoprotein in the context of individual tumor cells and the micro-environment<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>. This knowledge could assist in the future discovery of new therapeutic targets and in developing guidelines for risk stratification and treatment.</p><p class="" id=d1627e537>Currently, the strongest prognostic factor is stage at initial diagnosis. In North America, survival in localized ES improved to more than 70% 5-year event-free survival (EFS) by treating with alternating cycles of interval-compressed vincristine, doxorubicin, cyclophosphamide and ifosfamide and etoposide (VDC/IE)<sup><a href="#ref-6">6</a></sup>. The Euro-Ewing 99 clinical trial improved outcomes in localized ES with high-risk features by intensification of therapy with high-dose chemotherapy with busulfan and melphalan<sup><a href="#ref-7">7</a></sup>. The addition of IE cycles in earlier studies or intensification of therapy with high-dose chemotherapy has not improved outcomes for patients with metastatic disease<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. As patients with metastatic ES have not benefited from treatment intensification, it suggests that targeted agents will be needed for this population. As an example, an ongoing Childrenâ€™s Oncology Group (COG) trial is evaluating the insulin-like growth factor 1 receptor (IGF-1R) antibody ganitumab with cytotoxic chemotherapy (ClinicalTrials.gov Identifier: NCT02306161)<sup><a href="#ref-10">10</a></sup>. Patients with relapsed ES also have a dismal prognosis, and survival estimates are about 10%<sup><a href="#ref-1">1</a></sup>. Current efforts in the relapsed setting have focused on targeting EWS-FLI1 itself, targeting DNA damage vulnerabilities, or exploring immunotherapy strategies<sup><a href="#ref-11">11</a>â€“<a href="#ref-20">20</a></sup>. For the purpose of this report, we consider patients with either newly diagnosed metastatic or relapsed ES to have advanced disease. There is a dire need for new therapies to improve outcomes for patients with advanced ES.</p><p class="" id=d1627e571>It is in this clinical climate that the COG Bone Tumor Committee established the New Agents for Ewing Sarcoma Task Force. The COG Bone Tumor Committee previously established a successful working group for drug development in osteosarcoma<sup><a href="#ref-21">21</a></sup>. The purpose of this ongoing effort in ES is to bring together experts (basic scientists, experts in preclinical testing, pediatric sarcoma clinicians, and clinical investigators) with the primary goal of identifying potential agents of high priority for clinical evaluation and expeditiously incorporating these agents into clinical trials. Many new agents are being investigated in relapsed ES and many of these are listed in <a href="#T1">Table 1</a>. In this report, we summarize our work to date, including establishing a framework to prioritize potential agents in this rare disease, characterizing challenges in understanding the disease biology, determining the bar for preclinical data, recommending an appropriate cytotoxic chemotherapy backbone on which to layer novel agents, and highlighting practical considerations for clinical trial development in the advanced ES patient population. We aim to provide clinicians and basic scientistâ€™s insight into our approach in order to broadly facilitate discussions on moving new agents forward in this rare tumor. For additional background on ES more generally, we refer the reader to a recent review article<sup><a href="#ref-22">22</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Agents discussed and evaluated by New Agents for Ewing Sarcoma Task Force in 2018.</h3><p id=d1627e595>The agents appearing in a bold typeface are expanded upon in <a href="#T2">Table 2</a>.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d1627e602 class=n-a></a><thead><a name=d1627e604 class=n-a></a><tr><a name=d1627e606 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d1627e608 class=n-a></a>Drug/Target Class</th><th align=left colspan=1 rowspan=1><a name=d1627e611 class=n-a></a>Example drugs</th></tr></thead><tbody><a name=d1627e616 class=n-a></a><tr><a name=d1627e618 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e620 class=n-a></a>EWSR1-FLI1 Target agents:<br class=br>Splicing inhibitors<br class=br>Minor groove-binding agents</td><td colspan=1 rowspan=1><a name=d1627e627 class=n-a></a>TK-216<br class=br><br class=br>Mithramycin, Trabectedin and Lurbinectidin</td></tr><tr><a name=d1627e634 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e636 class=n-a></a>Epigenetic therapies</td><td colspan=1 rowspan=1><a name=d1627e639 class=n-a></a>Lysine-specific demethylase 1A (LSD1) inhibitors (seclidemstat and IMG-7289)<br class=br>Histone deacetylase inhibitors (vorinostat, entinostat, and panobinostat)<br class=br>Bromodomain inhibitors</td></tr><tr><a name=d1627e647 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e649 class=n-a></a>CD99 targeting agents</td><td colspan=1 rowspan=1><a name=d1627e652 class=n-a></a>Clofarabine/Cladribine and CD99 antibody</td></tr><tr><a name=d1627e656 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e658 class=n-a></a>Novel cytotoxic agents</td><td colspan=1 rowspan=1><a name=d1627e661 class=n-a></a> <b>Eribulin</b>, aldoxorubicin and palifosfamide</td></tr><tr><a name=d1627e668 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e670 class=n-a></a>Multi-targeted tyrosine Kinase Inhibitors</td><td colspan=1 rowspan=1><a name=d1627e673 class=n-a></a> <b>Pazopanib, regorafenib</b> and <b>cabozantinib</b> </td></tr><tr><a name=d1627e684 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e686 class=n-a></a>Mammalian target of rapamycin (mTOR) inhibitors</td><td colspan=1 rowspan=1><a name=d1627e689 class=n-a></a> <b>Nab-Rapamycin</b>, temsirolimus</td></tr><tr><a name=d1627e696 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e698 class=n-a></a>DNA damage/Repair</td><td colspan=1 rowspan=1><a name=d1627e701 class=n-a></a>Poly-ADP-ribose polymerase (PARP) inhibitors <b>(niraparib, olaparib, talazoparib)</b> <br class=br>Wee1 inhibitors (AZD1775)<br class=br>CHK1 inhibitors (prexasertib)</td></tr><tr><a name=d1627e712 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e714 class=n-a></a>Cell cycle cyclin-dependent kinase (CDK) inhibitors</td><td colspan=1 rowspan=1><a name=d1627e717 class=n-a></a>CDK4/6 Inhibitors <b>(palbociclib, ribociclib, abemaciclib)</b> </td></tr><tr><a name=d1627e724 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e726 class=n-a></a>Transcriptional CDK Inhibitors</td><td colspan=1 rowspan=1><a name=d1627e729 class=n-a></a>CDK7 inhibitor (SY-1365)<br class=br>CDK12 inhibitor</td></tr><tr><a name=d1627e735 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e737 class=n-a></a>MDM2 Inhibitor</td><td colspan=1 rowspan=1><a name=d1627e740 class=n-a></a>AMG-232, DS-3032b, ALRN-6924 and idasanutlin</td></tr><tr><a name=d1627e744 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e746 class=n-a></a>Insulin-like growth factor 1 receptor (IGF-1R)<br class=br>inhibitors</td><td colspan=1 rowspan=1><a name=d1627e751 class=n-a></a> <b>Ganitumab</b> </td></tr><tr><a name=d1627e759 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e761 class=n-a></a>Platelet-derived growth factor receptor (PDGFR)<br class=br>antibodies</td><td colspan=1 rowspan=1><a name=d1627e766 class=n-a></a>Olaratumab</td></tr><tr><a name=d1627e770 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e772 class=n-a></a>Other monoclonal antibodies</td><td colspan=1 rowspan=1><a name=d1627e775 class=n-a></a>MORab-004</td></tr><tr><a name=d1627e779 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e781 class=n-a></a>Metabolic modulators</td><td colspan=1 rowspan=1><a name=d1627e784 class=n-a></a>Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors and Metformin</td></tr><tr><a name=d1627e788 class=n-a></a><td colspan=1 rowspan=1><a name=d1627e790 class=n-a></a>Immunotherapy</td><td colspan=1 rowspan=1><a name=d1627e793 class=n-a></a>GD2 antibody <b>(dinutuximab)</b> <br class=br>VIGIL/FANG<br class=br>Chimeric antigen receptor (CAR) T cells</td></tr></tbody></table></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1627e810>Conceptual framework for assessing novel agents in advanced Ewing sarcoma</h2><p class="" id=d1627e813>The task force defined key criteria against which to gauge potential new agents of relevance to ES (<a href="#f1">Figure 1</a>). These criteria were broadly divided into non-clinical and clinical criteria.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/19837/8e465447-bc97-4810-b0bc-fc0b3af85644_figure1.gif"><img alt="8e465447-bc97-4810-b0bc-fc0b3af85644_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/19837/8e465447-bc97-4810-b0bc-fc0b3af85644_figure1.gif"></a><div class=caption><h3>Figure 1. Paradigm for evaluation new agents for Ewing sarcoma.</h3><p id=d1627e829>Task force members proposed agents or targets (detailed in <a href="#T1">Table 1</a>). These proposals were then each individually discussed using the step-wise approach outlined. Agents deemed worthy to move forward were then re-examined and re-vetted through this work flow as new preclinical or trial data updates became available. CTEP, Cancer Therapy Evaluation Program; EWS, Ewing sarcoma; FDA, US Food and Drug Administration.</p></div></div><div class=section><a name=d1627e839 class=n-a></a><h3 class=section-title>Non-clinical criteria</h3><p class="" id=d1627e844>The fundamental non-clinical criterion is the strength of the basic science evidence demonstrating that the target either is critical to ES pathogenesis or has an expression pattern that is relatively specific to ES. Mechanistic dependency may be linked directly to targeting the oncoprotein EWS-FLI or effectors downstream of EWS-FLI1 or micro-environmental factors critical to the tumor. Once a target is identified, it is crucial to have proof-of-concept data that a putative drug is active against the intended target.</p><p class="" id=d1627e847>In addition to proof-of-concept data, the remaining requirements for preclinical data will likely vary greatly depending on the agent and the model systems available. For example, although ideally animal model data would be obtained in the preclinical setting, acquiring animal data for immunotherapy agents is currently not optimal given the lack of transgenic and well-developed humanized mouse models of ES<sup><a href="#ref-23">23</a></sup>. Although a range of <i>in vitro</i> and <i>in vivo</i> supportive preclinical testing can be considered to help prioritize agents for further development, for a rare tumor such as ES for which relapse is nearly uniformly fatal, extensive preclinical testing need not be required if the rationale for the agent is otherwise strong. Preclinical data in ES have not always predicted clinical response; furthermore, the degree of testing is not standardized and particular attention to pharmacokinetics, pharmacodynamics, and the use of a clinically relevant dose and schedule is recommended to provide translational relevance<sup><a href="#ref-24">24</a>â€“<a href="#ref-28">28</a></sup>.</p></div><div class=section><a name=d1627e868 class=n-a></a><h3 class=section-title>Clinical criteria</h3><p class="" id=d1627e873>From a clinical perspective, the paramount criterion is a signal of activity in early-phase testing with agents meeting this criterion prioritized for rapid translation into a trial for relapsed or newly diagnosed metastatic populations. Drug availability, through US Food and Drug Administration (FDA) approval for other indications, inclusion in the Cancer Therapy Evaluation Program (CTEP) portfolio, or collaboration with an engaged industry partner, offers another factor in prioritization. Availability of pediatric dosing schedules is an advantage but not a prerequisite in this AYA cancer<sup><a href="#ref-29">29</a>â€“<a href="#ref-31">31</a></sup>. Given that single-agent therapy is unlikely to be curative in most circumstances, it is important to consider the feasibility of combination therapy. Other clinical parameters discussed are outlined in <a href="#f1">Figure 1</a>.</p><p class="" id=d1627e886>With these non-clinical and clinical criteria in place, we formulated a list of potential agents for advanced ES. <a href="#T1">Table 1</a> is an inclusive list of agents considered in 2018. We next methodically considered each agent in a step-wise fashion, applying the aforementioned criteria. We applied these criteria to selected potential agents of greatest interest (<a href="#T2">Table 2</a>). <a href="#T2">Table 2</a> also provides a benchmark for ganitumab, an agent currently in phase 3 testing in newly diagnosed metastatic ES, and for mammalian target of rapamycin (mTOR) inhibitors currently proposed for the next COG trial for first recurrence.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Work-flow summary of the top five promising agents in 2018.</h3><p id=d1627e908>Work-flow summary of eribulin, dinutuximab, tyrosine kinase inhibitors, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, and poly-ADP-ribase polymerase (PARP) inhibitors. Ganitumab (currently in a metastatic Ewing sarcoma clinical trial) and mammalian target of rapamycin (mTOR) inhibitors (currently in a trial proposal) are also included using the task forceâ€™s work flow for comparison.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d1627e912 class=n-a></a><thead><a name=d1627e914 class=n-a></a><tr><a name=d1627e916 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d1627e918 class=n-a></a>Drug</th><th align=center colspan=1 rowspan=1><a name=d1627e921 class=n-a></a>Basic<br class=br>Science<br class=br>Evidence</th><th align=center colspan=1 rowspan=1><a name=d1627e928 class=n-a></a>Preclinical<br class=br>Evidence</th><th align=center colspan=1 rowspan=1><a name=d1627e933 class=n-a></a>Clinical<br class=br>Evidence</th><th align=center colspan=1 rowspan=1><a name=d1627e938 class=n-a></a>Drug<br class=br>Availability</th><th align=center colspan=1 rowspan=1><a name=d1627e944 class=n-a></a>Trial Design<br class=br>Consideration</th><th align=center colspan=1 rowspan=1><a name=d1627e949 class=n-a></a>Consensus<br class=br>Decision</th></tr></thead><tbody><a name=d1627e956 class=n-a></a><tr><a name=d1627e958 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d1627e960 class=n-a></a> <b>Ganitumab</b><br class=br>(in trial)</td><td align=center colspan=1 rowspan=1><a name=d1627e967 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e970 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e973 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e976 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e980 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e983 class=n-a></a>In trial<br class=br>(AEWS1221)</td></tr><tr><a name=d1627e989 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d1627e991 class=n-a></a> <b>mTOR inhibitor</b><br class=br><b>(proposed trial)</b> </td><td align=center colspan=1 rowspan=1><a name=d1627e1000 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1003 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e1006 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e1009 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1013 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1016 class=n-a></a>Move forward</td></tr><tr><a name=d1627e1020 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d1627e1022 class=n-a></a> <b>Anti-GD2</b><br class=br><b>monoclonal</b> </td><td align=center colspan=1 rowspan=1><a name=d1627e1031 class=n-a></a>++</td><td colspan=1 rowspan=1><a name=d1627e1034 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d1627e1036 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e1039 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1043 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1046 class=n-a></a>Move forward</td></tr><tr><a name=d1627e1050 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d1627e1052 class=n-a></a> <b>Eribulin</b> </td><td align=center colspan=1 rowspan=1><a name=d1627e1058 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e1061 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e1064 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e1067 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1071 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1074 class=n-a></a>In early trials</td></tr><tr><a name=d1627e1078 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d1627e1080 class=n-a></a> <b>Multi-targeted</b><br class=br><b>tyrosine kinase</b><br class=br><b>inhibitor</b> </td><td align=center colspan=1 rowspan=1><a name=d1627e1092 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e1095 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e1098 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e1101 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1105 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e1108 class=n-a></a>In early trials</td></tr><tr><a name=d1627e1113 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d1627e1115 class=n-a></a> <b>CDK4/6 inhibitor</b> </td><td align=center colspan=1 rowspan=1><a name=d1627e1121 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1124 class=n-a></a>++</td><td colspan=1 rowspan=1><a name=d1627e1127 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d1627e1129 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1133 class=n-a></a>+</td><td align=center colspan=1 rowspan=1><a name=d1627e1136 class=n-a></a>In early trials</td></tr><tr><a name=d1627e1140 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d1627e1142 class=n-a></a> <b>PARP inhibitor</b> </td><td align=center colspan=1 rowspan=1><a name=d1627e1148 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1151 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1154 class=n-a></a>-</td><td align=center colspan=1 rowspan=1><a name=d1627e1157 class=n-a></a>++</td><td align=center colspan=1 rowspan=1><a name=d1627e1161 class=n-a></a>-</td><td align=center colspan=1 rowspan=1><a name=d1627e1164 class=n-a></a>In early trials</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d1627e1172 class=n-a></a><p id=d1627e1174> <b>Table 2 - = negative data, + =some evidence, ++ =significant evidence, blank=no data</b> </p></div></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1627e1187>Eribulin</h2><p class="" id=d1627e1190>Eribulin is a microtubule inhibitor that inhibits polymerization of tubulin subunits and differs from other microtubule inhibitors by preventing lengthening and shortening of microtubules during division. Aggregation of unstable tubulin polymers ultimately results in cellular apoptosis<sup><a href="#ref-32">32</a>â€“<a href="#ref-35">35</a></sup>. EWS-FLI1 is known to drive the expression of proteins that regulate microtubule stability<sup><a href="#ref-15">15</a></sup>. Preclinical testing of ES cell lines demonstrated apoptosis, induced through the Bcl-2 pathway<sup><a href="#ref-36">36</a></sup>. Eribulin was also evaluated by the Pediatric Preclinical Testing Program (PPTP); four out of five ES xenografts demonstrated a complete response to treatment<sup><a href="#ref-37">37</a></sup>. In sarcoma treatment, eribulin is FDA-approved for adult patients with liposarcoma who previously received an anthracycline<sup><a href="#ref-38">38</a></sup>. The COG performed a phase 1 trial of eribulin in children with advanced solid tumors; one of the evaluable patients with ES experienced a partial response for four cycles<sup><a href="#ref-39">39</a></sup>. An ongoing phase 2 trial (ClinicalTrials.gov Identifier: NCT03441360) is assessing eribulin in patients with relapsed ES<sup><a href="#ref-40">40</a></sup>. An ongoing phase 1/2 trial (ClinicalTrials.gov Identifier: NCT03245450) is evaluating eribulin in combination with irinotecan, although these agents are not expected to have significant overlapping toxicities<sup><a href="#ref-41">41</a></sup>. Furthermore, vincristine and topoisomerase 1 inhibitors act synergistically in xenograft models and in pediatric clinical trials; therefore, eribulin with irinotecan may also have clinical synergy<sup><a href="#ref-42">42</a>,<a href="#ref-43">43</a></sup>.</p><p class="" id=d1627e1236>Eribulin shows strong preclinical data in ES, is an FDA-approved agent for another sarcoma indication, and has led to at least one monotherapy response in relapsed ES. We will recommend further trial development with eribulin as a component of combination therapy pending the results of current trials.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1627e1242>Dinutuximab</h2><p class="" id=d1627e1245>GD2 is a disialoganglioside that is expressed on the surface of tumors of neural crest origin, such as neuroblastoma<sup><a href="#ref-44">44</a></sup>. The precise cell of origin for ES is unknown; however, it is thought to be a neural crest or mesenchymal-derived tumor<sup><a href="#ref-45">45</a>â€“<a href="#ref-47">47</a></sup>. ES tumors have been evaluated for GD2 expression, and results range from no detectable surface expression to diffuse/intense staining in some tumors<sup><a href="#ref-48">48</a>â€“<a href="#ref-51">51</a></sup>. It is not known whether GD2 expression changes upon relapse or whether levels differ in patients with newly diagnosed metastatic ES. Several available antibodies in the clinic are known to bind to this target, including dinutuximab, which is approved by the FDA for use in neuroblastoma. There is currently no preclinical evidence for utility of dinutuximab in ES.</p><p class="" id=d1627e1266>The clinical evidence supporting dinutuximab borrows heavily from another GD2-positive pediatric cancer, neuroblastoma. The combination of irinotecan, temozolomide, and dinutuximab has been shown to demonstrate significant clinical benefit in children with advanced neuroblastoma<sup><a href="#ref-52">52</a></sup>. Pediatric dosing, schedules, and toxicities are well documented with this therapy combination. Patients with relapsed neuroblastoma are generally younger than patients with relapsed ES, and there is the potential for different toxicity in older patients. As some ES tumors express GD2, determining whether the addition of dinutuximab to chemotherapy extends to ES is a logical clinical trial question. Dinutuximab is FDA-approved and also available in the CTEP portfolio. As demonstrated in neuroblastoma trials, dinutuximab is both feasible and more effective in combination with irinotecan and temozolomide (IT).</p><p class="" id=d1627e1273>The task force determined that the available clinical data in another GD2-positive tumor treated with this combination are sufficiently strong to nominate this approach for clinical evaluation in ES. Irinotecan and temozolomide are agents routinely used in relapsed ES therapy, and a next-step trial could determine the efficacy of dinutuximab added to IT. The combination would be strategically combining immune-based treatment with traditional cytotoxic therapy. Given the current inconsistency in GD2 immunohistochemistry staining, it would not be possible to select patients upfront on the basis of tumor GD2 expression.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1627e1279>Anti-angiogenic tyrosine kinase inhibitors</h2><p class="" id=d1627e1282>A large body of work highlights the role of angiogenesis in ES<sup><a href="#ref-53">53</a>â€“<a href="#ref-56">56</a></sup>. Several tyrosine kinase inhibitors (TKIs) targeting angiogenesis have been developed, although most are multi-targeted TKIs that target other receptor tyrosine kinases (RTKs). RTKs are important regulators of cell growth, proliferation, and survival. Aberrant RTK signaling resulting from amplification, mutation, or overexpression has been implicated in many cancers, including ES<sup><a href="#ref-57">57</a></sup>.</p><p class="" id=d1627e1296>Pazopanib primarily targets VEGFR-1 and -2, PDGFR-Î± and -Î², and c-Kit<sup><a href="#ref-58">58</a></sup>. Pazopanib has gained FDA approval for treatment of refractory soft tissue sarcoma (STS) in adult patients. A phase 3 clinical trial for patients with advanced STS demonstrated improved progression-free survival (PFS) (4.6 months) in the pazopanib arm compared with placebo (1.6 months)<sup><a href="#ref-59">59</a></sup>. The PPTP evaluation of pazopanib revealed a statistically prolonged EFS in ES xenografts but no objective responses<sup><a href="#ref-60">60</a></sup>. Several case reports have demonstrated partial responses in patients with ES; however, resistance seems to develop with prolonged use<sup><a href="#ref-61">61</a>â€“<a href="#ref-63">63</a></sup>. Cabozantinib targets VEGFR2, c-MET, and AXL and is FDA-approved for the treatment of medullary thyroid cancer and renal cell carcinoma in adults. A phase 2 study of cabozantinib in patients with recurrent ES showed tumor control with 9 (27.7%) partial responses and 10 (30.3%) with stable disease<sup><a href="#ref-64">64</a></sup>. Pediatric phase 2 dosing is established for both pazopanib and cabozantinib<sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup>. Regorafenib is an oral multikinase inhibitor that targets VEGFR-1-3, FGFR1, PDGFR-Î± and -Î², CSFR-1, and c-Kit. It has FDA approval for use in metastatic colorectal carcinoma, gastrointestinal stromal tumor, and hepatocellular carcinoma. SARC024 evaluated regorafenib in 30 patients with ES. The median PFS was 3.6 months, and the median duration of response was 5.5 months<sup><a href="#ref-67">67</a></sup>.</p><p class="" id=d1627e1334>At least three anti-angiogenic TKIs have shown clinical monotherapy activity in relapsed ES. This clinical activity together with preclinical rationale and drug availability should motivate evaluation of this class of agents in combination with cytotoxic chemotherapy or other targeted agents or as a potential maintenance therapy in future trials.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1627e1341>CDK4/6 inhibitors</h2><p class="" id=d1627e1344> <i>CDKN2A</i> is a gene that codes for two proteins: p16 and p14arf. Both proteins are tumor suppressors; p16 inhibits cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) by phosphorylating the RB protein, thus preventing cell cycle progression<sup><a href="#ref-68">68</a></sup>. About 13 to 30% of ES tumors have deletions in <i>CDKN2A</i><sup><a href="#ref-69">69</a>â€“<a href="#ref-71">71</a></sup>. <i>CDKN2A</i> deletion does not appear to be associated with clinical outcome<sup><a href="#ref-72">72</a></sup>. Owing to the alteration of p16 in a subset of ES, there is clinical interest in CDK4/6 inhibitors that target and inhibit this pathway. The cyclin D1 gene has been shown to be associated with a superenhancer in ES<sup><a href="#ref-73">73</a></sup>. ES cells consequently have an activated cyclin D1/CDK4 pathway and require CDK4 and cyclin D1 for growth. <i>In vivo</i> data demonstrated decreased tumor growth and prolonged survival with CDK4/6 inhibition<sup><a href="#ref-73">73</a></sup>. These data provide a rationale for use even in the absence of <i>CDKN2A</i> deletions<sup><a href="#ref-74">74</a></sup>.</p><p class="" id=d1627e1389>Currently, three CDK4/6 inhibitors have been FDA-approved for advanced breast cancer: abemaciclib, palbociclib, and ribociclib. These agents each have ongoing or completed single-agent pediatric phase 1 trials (ClinicalTrials.gov Identifiers: NCT02644460, NCT01747876, and NCT02255461)<sup><a href="#ref-75">75</a>â€“<a href="#ref-77">77</a></sup>. As in adults, the predominant toxicity seen in children is hematologic<sup><a href="#ref-78">78</a></sup>. Since single-agent therapy is rarely curative in sarcomas, there is little interest in evaluating single-agent CDK4/6 inhibitors in patients with ES. Combination with conventional cytotoxic chemotherapy agents, many of which are dependent on S-phase cycling, may be challenging because of antagonistic mechanisms<sup><a href="#ref-79">79</a></sup>. Furthermore, the significant myelosuppression seen with CDK4/6 inhibitors complicates combinatorial therapy. Without significant adult data evaluating CDK4/6 inhibitors with chemotherapy, we await the results of a planned trial evaluating palbociclib with IT before recommending a chemotherapy combination approach in advanced ES (ClinicalTrials.gov Identifier: NCT03709680)<sup><a href="#ref-80">80</a></sup>. There are other trials in the US combining CDK4/6 inhibitors with agents, including MEK and mTOR inhibitors (ClinicalTrials.gov Identifiers: NCT03387020, NCT03114527, and NCT02703571)<sup><a href="#ref-81">81</a>â€“<a href="#ref-83">83</a></sup>. Other preclinical data suggest that dual inhibition of CDK4/6 and IGF-1R may be a combination to consider in ES, as CDK4/6 drug resistance is mediated by activation of IGF-1R signaling<sup><a href="#ref-84">84</a></sup>. In sum, CDK4/6 inhibitors have potential efficacy in ES but identifying the appropriate combination therapy has been challenging. We recommend additional preclinical and clinical data before moving this class of drugs forward in first-relapse or metastatic ES.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1627e1426>PARP inhibitors</h2><p class="" id=d1627e1429>Much enthusiasm has surrounded poly-ADP-ribose polymerase 1 (PARP1) inhibitors in ES. PARP plays a significant role in DNA repair, particularly with single-strand DNA damage. Inhibition of PARP proteins can cause persistent single-strand breaks, ultimately resulting in cellular apoptosis. EWS-FLI1 interacts with PARP1, influencing its transcriptional activity, and ES tumors have high levels of PARP mRNA and protein activity<sup><a href="#ref-85">85</a></sup>. Several PARP inhibitors, including olaparib, rucaparib, talazoparib, and niraparib, have received FDA approval for the treatment of ovarian or breast cancer in adult patients. Interest in PARP inhibitors in ES resulted from preclinical data demonstrating sensitivity in ES cell lines<sup><a href="#ref-86">86</a></sup>. A phase 2 trial with olaparib monotherapy quickly opened for adults with relapsed ES. Of the 12 patients enrolled, none had objective responses and four patients had stable disease. The median time to progression was 5.7 weeks<sup><a href="#ref-25">25</a></sup>. The PPTP and others evaluated PARP inhibitors in combination with DNA-damaging chemotherapy and demonstrated activity in ES xenografts<sup><a href="#ref-87">87</a>â€“<a href="#ref-89">89</a></sup>.</p><p class="" id=d1627e1451>Owing to these promising preclinical data, a series of successor trials have evaluated PARP inhibitors in combination with irinotecan, temozolomide, or IT (ClinicalTrials.gov Identifiers: NCT02116777, NCT01858168, NCT02044120, and NCT02392793)<sup><a href="#ref-90">90</a>â€“<a href="#ref-93">93</a></sup>. While there have been hints of clinical activity, preliminary presentations of the toxicity data have shown that the myelosuppression of PARP inhibitors with cytotoxic chemotherapy is limiting dose intensity in these combination trials<sup><a href="#ref-94">94</a></sup>. This drug class demonstrates that strong preclinical activity and rationale may not always predict clinical feasibility, particularly in a heavily pretreated, relapsed patient population. At this time, we recommend awaiting results from ongoing clinical trials prior to moving this class of drugs further in advanced ES clinical trials.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1627e1468>The cytotoxic backbone: trial recommendations</h2><p class="" id=d1627e1471>We also discussed the chemotherapy backbone onto which selected agents could be added for patients with first recurrent ES. Currently, there is no established standard backbone for patients with recurrent or refractory ES. Topotecan with cyclophosphamide has shown activity in patients with relapsed ES with response rates between 23 and 41%<sup><a href="#ref-95">95</a>â€“<a href="#ref-100">100</a></sup>. Owing to this promising activity, the COG conducted a pilot trial adding vincristine, topotecan, and cyclophosphamide (VTc) to interval-compressed ES therapy. This combination was tolerable, but hematologic toxicity was between 44 and 63%<sup><a href="#ref-101">101</a></sup>. The Euro Ewing Consortium is evaluating topotecan and cyclophosphamide in the rEECur trial (EudraCT number: 2014-000259-99) for recurrent ES. A randomized COG phase 3 trial, AEWS1031, evaluated the efficacy of adding VTc to the interval-compressed five-drug backbone, and results are pending. Owing to the significant hematologic toxicity of this combination, incorporating additional agents to this backbone may prove challenging but could be considered for the appropriate novel agents.</p><p class="" id=d1627e1485>The combination of vincristine and IT (VIT) has also shown activity in patients with relapsed ES. VIT has demonstrated response rates between 29 and 63% in relapsed or refractory patients, although the actual VIT response rate has not yet been investigated in a prospective randomized trial<sup><a href="#ref-102">102</a>â€“<a href="#ref-105">105</a></sup>. This chemotherapy has schedule-dependent synergy<sup><a href="#ref-106">106</a>,<a href="#ref-107">107</a></sup>. The combination of drugs also has limited overlapping toxicity. Diarrhea and abdominal pain are the most common dose-limiting toxicities of irinotecan<sup><a href="#ref-108">108</a>,<a href="#ref-109">109</a></sup>. The major dose-limiting toxicity of temozolomide is myelosuppression<sup><a href="#ref-110">110</a>â€“<a href="#ref-112">112</a></sup>. Currently, the Euro Ewing Consortium is evaluating IT in relapsed ES. IT has a strong history of efficacious combination with monoclonal antibodies or targeted therapies in other diseases<sup><a href="#ref-52">52</a>,<a href="#ref-113">113</a>,<a href="#ref-114">114</a></sup>. Currently, there are ongoing trials for patients with ES combining IT with PARP inhibitors or Vigil autologous vaccine (ClinicalTrials.gov Identifiers: NCT02044120, NCT01858168, and NCT03495921)<sup><a href="#ref-90">90</a>,<a href="#ref-92">92</a>,<a href="#ref-93">93</a>,<a href="#ref-115">115</a></sup>. Owing to the reported efficacy of IT in ES and successful combination with other novel therapeutics, we believe IT (with or without vincristine) may be a preferred and feasible cytotoxic backbone for future combination clinical trials in first recurrent ES.</p><p class="" id=d1627e1540>Although the original addition of IE to VDC did show improved outcomes for localized disease, patients with upfront metastatic ES saw no clinical benefit from this addition<sup><a href="#ref-8">8</a>,<a href="#ref-116">116</a>,<a href="#ref-117">117</a></sup>. Given these data, the group also discussed eliminating or reducing IE cycles for metastatic patients to decrease toxicity, allowing the addition of other targeted agents to VDC in future trials. Furthermore, early data from a single-institution trial including patients with upfront metastatic ES (ClinicalTrials.gov Identifier: NCT01864109) demonstrate the feasibility of incorporating IT into standard upfront therapy for metastatic ES<sup><a href="#ref-118">118</a></sup>. Altering the number of IE cycles and adding IT to the upfront chemotherapy backbone are both considerations for further trial design considering drug synergism and overlapping toxicities of the targeted agents being studied.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1627e1560>Additional key clinical trial design considerations</h2><p class="" id=d1627e1563>In addition to establishing recommendations for advanced ES cytotoxic backbones, we examined other important aspects of trial design including patient randomization, maintenance therapy, and specific differences in trial design approach for patients with upfront metastatic versus relapsed ES. Given the rarity of this tumor, we continue to support collaborative, multi-national trials in order to study this cancer in a timely and inclusive manner.</p><p class="" id=d1627e1566>With a goal of testing novel agents in patients with advanced ES, we propose several potential trial designs depending upon the agent and specific population of interest. The newly diagnosed metastatic population presents two potential opportunities for evaluating new agents. For agents expected to combine well with conventional cytotoxic chemotherapy, we recommend a randomized design comparing chemotherapy alone versus chemotherapy plus a novel agent. Depending upon the available evidence supporting the agent, the statistical parameters for such a trial may incorporate a phase 2 design with early stopping rules or a phase 3 trial to show definitive efficacy. For agents difficult to combine with chemotherapy, those that may be administered on a chronic schedule, or those with expected efficacy in minimal residual disease settings, a maintenance design could be considered. In this design, patients in a radiographic complete remission would continue treatment with the novel agent upon completion of frontline therapy. Both approaches are used in the ongoing COG trial of ganitumab. Given the paucity of clinical data for maintenance strategies in ES, this approach is best studied in the context of a randomized study, comparing maintenance with no maintenance or comparing two different promising maintenance strategies. Likewise, the type of maintenance regimen should be carefully considered in light of concerns about toxicity and adherence in an AYA population<sup><a href="#ref-119">119</a></sup>.</p><p class="" id=d1627e1573>For the relapse population, there are two main design considerations. Given that ES often remains chemotherapy-responsive at first relapse, trial designs should incorporate cytotoxic chemotherapy. Therefore, testing of new agents can be performed as a single-arm trial combining a new agent with a standard backbone, and inference about activity of the combination is based on strong historical data for the backbone regimen. Alternatively, new agents may be tested in a randomized manner, either as a definitive comparison against the backbone alone or in a selection design comparing two novel agents added to the same backbone. Promising agents that are unlikely to pair well with chemotherapy (for example, antagonism; overlapping toxicity) may be best evaluated as monotherapy in a second relapse population.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1627e1579>Conclusions and future directions</h2><p class="" id=d1627e1582>We have generated a robust group and infrastructure for vetting novel agents for evaluation in patients with ES. Future efforts by our group and other groups may use this paradigm as new agents or concepts become available. We discussed several strategies that were determined to be too early in development for immediate translation into a clinical trial for the newly diagnosed metastatic or first recurrent populations. Examples of these strategies include lysine-specific demethylase 1A (LSD1) inhibition, inhibition of interaction between EWSR1-FLI1 protein with RNA helicase, epigenetic modification of chromatin modeling resulting in EWS-FLI1 suppression, inhibition of transcriptionally active CDKs, and immunotherapy approaches in ES<sup><a href="#ref-17">17</a>,<a href="#ref-120">120</a>â€“<a href="#ref-122">122</a></sup>. The first two of these approaches are particularly noteworthy as they target fundamental functions of the fusion oncoprotein that drives this disease. The task force will continue to discuss the progress of these and other emerging strategies.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d1627e1 class=n-a></a><h2 class=main-title id=d1980>Grant information</h2><p>This work is supported by the Childrenâ€™s Oncology Group and the National Cancer Institute of the National Institutes of Health under NCTN Operations Center Grant U10CA180886.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d1627e1599 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d2387>References</h2><div class="section ref-list"><a name=d1627e1599 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d1627e1606 class=n-a></a>Lawlor ER, Sorensen PH: Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward? <i>Crit Rev Oncog.</i> 2015; <b>20</b>(3â€“4): 155â€“71. <a target=xrefwindow id=d1627e1614 href="http://www.ncbi.nlm.nih.gov/pubmed/26349414">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1617 href="https://doi.org/10.1615/CritRevOncog.2015013553">Publisher Full Text </a> | <a target=xrefwindow id=d1627e1620 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4671490">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733885107"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e1629 class=n-a></a>Anderson ND, de Borja R, Young MD, <i> et al.</i>: Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. <i>Science.</i> 2018; <b>361</b>(6405): pii: eaam8419. <a target=xrefwindow id=d1627e1640 href="http://www.ncbi.nlm.nih.gov/pubmed/30166462">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1643 href="https://doi.org/10.1126/science.aam8419">Publisher Full Text </a> | <a target=xrefwindow id=d1627e1647 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6176908">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733885107">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727244588"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e1660 class=n-a></a>Brohl AS, Patidar R, Turner CE, <i> et al.</i>: Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. <i>Genet Med.</i> 2017; <b>19</b>(8): 955â€“8. <a target=xrefwindow id=d1627e1671 href="http://www.ncbi.nlm.nih.gov/pubmed/28125078">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1674 href="https://doi.org/10.1038/gim.2016.206">Publisher Full Text </a> | <a target=xrefwindow id=d1627e1678 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5529247">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727244588">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727252021"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e1691 class=n-a></a>Franzetti GA, Laud-Duval K, van der Ent W, <i> et al.</i>: Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. <i>Oncogene.</i> 2017; <b>36</b>(25): 3505â€“14. <a target=xrefwindow id=d1627e1702 href="http://www.ncbi.nlm.nih.gov/pubmed/28135250">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1705 href="https://doi.org/10.1038/onc.2016.498">Publisher Full Text </a> | <a target=xrefwindow id=d1627e1709 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5541267">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727252021">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d1627e1722 class=n-a></a>Pedersen EA, Menon R, Bailey KM, <i> et al.</i>: Activation of Wnt/Î²-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States. <i>Cancer Res.</i> 2016; <b>76</b>(17): 5040â€“53. <a target=xrefwindow id=d1627e1733 href="http://www.ncbi.nlm.nih.gov/pubmed/27364557">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1736 href="https://doi.org/10.1158/0008-5472.CAN-15-3422">Publisher Full Text </a> | <a target=xrefwindow id=d1627e1740 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5010452">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717961055"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e1750 class=n-a></a>Womer RB, West DC, Krailo MD, <i> et al.</i>: Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. <i>J Clin Oncol.</i> 2012; <b>30</b>(33): 4148â€“54. <a target=xrefwindow id=d1627e1761 href="http://www.ncbi.nlm.nih.gov/pubmed/23091096">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1764 href="https://doi.org/10.1200/JCO.2011.41.5703">Publisher Full Text </a> | <a target=xrefwindow id=d1627e1768 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3494838">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717961055">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733954074"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e1781 class=n-a></a>Whelan J, Le Deley MC, Dirksen U, <i> et al.</i>: High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. <i>J Clin Oncol.</i> 2018; <b>36</b>(31): 3110â€“9. <a target=xrefwindow id=d1627e1792 href="http://www.ncbi.nlm.nih.gov/pubmed/30188789">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1795 href="https://doi.org/10.1200/JCO.2018.78.2516">Publisher Full Text </a> | <a target=xrefwindow id=d1627e1799 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6209090">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733954074">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d1627e1812 class=n-a></a>Grier HE, Krailo MD, Tarbell NJ, <i> et al.</i>: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. <i>N Engl J Med.</i> 2003; <b>348</b>(8): 694â€“701. <a target=xrefwindow id=d1627e1823 href="http://www.ncbi.nlm.nih.gov/pubmed/12594313">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1826 href="https://doi.org/10.1056/NEJMoa020890">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3790956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e1835 class=n-a></a>Ladenstein R, PÃ¶tschger U, Le Deley MC, <i> et al.</i>: Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. <i>J Clin Oncol.</i> 2010; <b>28</b>(20): 3284â€“91. <a target=xrefwindow id=d1627e1846 href="http://www.ncbi.nlm.nih.gov/pubmed/20547982">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1849 href="https://doi.org/10.1200/JCO.2009.22.9864">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3790956">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d1627e1862 class=n-a></a>NCT02306161: National Cancer Institute, Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma. In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e1864 href="https://www.clinicaltrials.gov/ct2/show/NCT02306161?term=NCT02306161&amp;rank=1">Reference Source</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d1627e1873 class=n-a></a>Theisen ER, Pishas KI, Saund RS, <i> et al.</i>: Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition <i>via</i> LSD1 targeting. <i>Oncotarget.</i> 2016; <b>7</b>(14): 17616â€“30. <a target=xrefwindow id=d1627e1887 href="http://www.ncbi.nlm.nih.gov/pubmed/26848860">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1891 href="https://doi.org/10.18632/oncotarget.7124">Publisher Full Text </a> | <a target=xrefwindow id=d1627e1894 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4951237">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d1627e1904 class=n-a></a>Gorthi A, Romero JC, Loranc E, <i> et al.</i>: EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. <i>Nature.</i> 2018; <b>555</b>(7696): 387â€“91. <a target=xrefwindow id=d1627e1915 href="http://www.ncbi.nlm.nih.gov/pubmed/29513652">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1918 href="https://doi.org/10.1038/nature25748">Publisher Full Text </a> | <a target=xrefwindow id=d1627e1922 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6318124">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734078593"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e1931 class=n-a></a>Gorthi A, Bishop AJR: Ewing sarcoma fusion oncogene: At the crossroads of transcription and DNA damage response. <i>Mol Cell Oncol.</i> 2018; <b>5</b>(4): e1465014. <a target=xrefwindow id=d1627e1939 href="http://www.ncbi.nlm.nih.gov/pubmed/30250915">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1942 href="https://doi.org/10.1080/23723556.2018.1465014">Publisher Full Text </a> | <a target=xrefwindow id=d1627e1945 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6149845">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734078593">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731932303"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e1958 class=n-a></a>Tawbi HA, Burgess M, Bolejack V, <i> et al.</i>: Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncol.</i> 2017; <b>18</b>(11): 1493â€“1501. <a target=xrefwindow id=d1627e1969 href="http://www.ncbi.nlm.nih.gov/pubmed/28988646">PubMed Abstract </a> | <a target=xrefwindow id=d1627e1972 href="https://doi.org/10.1016/S1470-2045(17)30624-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731932303">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731737018"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e1985 class=n-a></a>ZÃ¶llner SK, Selvanathan SP, Graham GT, <i> et al.</i>: Inhibition of the oncogenic fusion protein EWS-FLI1 causes G<sub>2</sub>-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma. <i>Sci Signal.</i> 2017; <b>10</b>(499): pii: eaam8429. <a target=xrefwindow id=d1627e1999 href="http://www.ncbi.nlm.nih.gov/pubmed/28974650">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2003 href="https://doi.org/10.1126/scisignal.aam8429">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731737018">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d1627e2016 class=n-a></a>Stegmaier K, Wong JS, Ross KN, <i> et al.</i>: Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. <i>PLoS Med.</i> 2007; <b>4</b>(4): e122. <a target=xrefwindow id=d1627e2027 href="http://www.ncbi.nlm.nih.gov/pubmed/17425403">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2030 href="https://doi.org/10.1371/journal.pmed.0040122">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2034 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1851624">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1161799"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2043 class=n-a></a>Erkizan HV, Kong Y, Merchant M, <i> et al.</i>: A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. <i>Nat Med.</i> 2009; <b>15</b>(7): 750â€“6. <a target=xrefwindow id=d1627e2054 href="http://www.ncbi.nlm.nih.gov/pubmed/19584866">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2057 href="https://doi.org/10.1038/nm.1983">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2061 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2777681">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1161799">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11190957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2075 class=n-a></a>Grohar PJ, Woldemichael GM, Griffin LB, <i> et al.</i>: Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. <i>J Natl Cancer Inst.</i> 2011; <b>103</b>(12): 962â€“78. <a target=xrefwindow id=d1627e2086 href="http://www.ncbi.nlm.nih.gov/pubmed/21653923">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2089 href="https://doi.org/10.1093/jnci/djr156">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2093 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3119649">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11190957">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d1627e2106 class=n-a></a>Grohar PJ, Griffin LB, Yeung C, <i> et al.</i>: Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. <i>Neoplasia.</i> 2011; <b>13</b>(2): 145â€“53. <a target=xrefwindow id=d1627e2117 href="http://www.ncbi.nlm.nih.gov/pubmed/21403840">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2120 href="https://doi.org/10.1593/neo.101202">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2124 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3033593">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d1627e2133 class=n-a></a>Boro A, PrÃªtre K, Rechfeld F, <i> et al.</i>: Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. <i>Int J Cancer.</i> 2012; <b>131</b>(9): 2153â€“64. <a target=xrefwindow id=d1627e2144 href="http://www.ncbi.nlm.nih.gov/pubmed/22323082">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2147 href="https://doi.org/10.1002/ijc.27472">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d1627e2156 class=n-a></a>Khanna C, Fan TM, Gorlick R, <i> et al.</i>: Toward a drug development path that targets metastatic progression in osteosarcoma. <i>Clin Cancer Res.</i> 2014; <b>20</b>(16): 4200â€“9. <a target=xrefwindow id=d1627e2167 href="http://www.ncbi.nlm.nih.gov/pubmed/24803583">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2170 href="https://doi.org/10.1158/1078-0432.CCR-13-2574">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2174 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4134738">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733602530"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2183 class=n-a></a>GrÃ¼newald TGP, Cidre-Aranaz F, Surdez D, <i> et al.</i>: Ewing sarcoma. <i>Nat Rev Dis Primers.</i> 2018; <b>4</b>(1): 5. <a target=xrefwindow id=d1627e2194 href="http://www.ncbi.nlm.nih.gov/pubmed/29977059">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2197 href="https://doi.org/10.1038/s41572-018-0003-x">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733602530">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726363754"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2210 class=n-a></a>Minas TZ, Surdez D, Javaheri T, <i> et al.</i>: Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. <i>Oncotarget.</i> 2017; <b>8</b>(21): 34141â€“63. <a target=xrefwindow id=d1627e2221 href="http://www.ncbi.nlm.nih.gov/pubmed/27191748">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2224 href="https://doi.org/10.18632/oncotarget.9388">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2228 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5470957">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726363754">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d1627e2242 class=n-a></a>DuBois SG, Krailo MD, Lessnick SL, <i> et al.</i>: Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. <i>Pediatr Blood Cancer.</i> 2009; <b>52</b>(3): 324â€“7. <a target=xrefwindow id=d1627e2253 href="http://www.ncbi.nlm.nih.gov/pubmed/18989890">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2256 href="https://doi.org/10.1002/pbc.21822">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2260 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2791370">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725227692"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2269 class=n-a></a>Choy E, Butrynski JE, Harmon DC, <i> et al.</i>: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. <i>BMC Cancer.</i> 2014; <b>14</b>: 813. <a target=xrefwindow id=d1627e2280 href="http://www.ncbi.nlm.nih.gov/pubmed/25374341">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2283 href="https://doi.org/10.1186/1471-2407-14-813">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2287 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4230717">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725227692">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d1627e2300 class=n-a></a>Houghton PJ, Morton CL, Kang M, <i> et al.</i>: Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. <i>Pediatr Blood Cancer.</i> 2010; <b>55</b>(6): 1224â€“6. <a target=xrefwindow id=d1627e2311 href="http://www.ncbi.nlm.nih.gov/pubmed/20979180">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2314 href="https://doi.org/10.1002/pbc.22355">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2318 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4675330">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d1627e2327 class=n-a></a>Scheinberg T, Lomax A, Martin HN, <i> et al.</i>: PD-1 blockage using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. <i>J Clin Oncol.</i> 2017; <b>35</b>(15_suppl): 3060. <a target=xrefwindow id=d1627e2338 href="https://doi.org/10.1200/JCO.2017.35.15_suppl.3060">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d1627e2347 class=n-a></a>Langenau DM, Sweet-Cordero A, Wechsler-Reya RJ, <i> et al.</i>: Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer. <i>Cancer Res.</i> 2015; <b>75</b>(24): 5176â€“86. <a target=xrefwindow id=d1627e2358 href="http://www.ncbi.nlm.nih.gov/pubmed/26627009">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2361 href="https://doi.org/10.1158/0008-5472.CAN-15-1308">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2365 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4681628">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726887980"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2374 class=n-a></a>Chuk MK, Mulugeta Y, Roth-Cline M, <i> et al.</i>: Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents. <i>Clin Cancer Res.</i> 2017; <b>23</b>(1): 9â€“12. <a target=xrefwindow id=d1627e2385 href="http://www.ncbi.nlm.nih.gov/pubmed/27780857">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2388 href="https://doi.org/10.1158/1078-0432.CCR-16-1367">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2392 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5217169">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726887980">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732528873"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2406 class=n-a></a>Gaspar N, Marshall LV, Binner D, <i> et al.</i>: Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: Proposals from the multi-stakeholder platformâ€”ACCELERATE. <i>Ann Oncol.</i> 2018; <b>29</b>(3): 766â€“71. <a target=xrefwindow id=d1627e2417 href="http://www.ncbi.nlm.nih.gov/pubmed/29351570">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2420 href="https://doi.org/10.1093/annonc/mdy002">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2424 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5889024">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732528873">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731602701"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2437 class=n-a></a>Gore L, Ivy SP, Balis FM, <i> et al.</i>: Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group. <i>J Clin Oncol.</i> 2017; <b>35</b>(33): 3781â€“7. <a target=xrefwindow id=d1627e2448 href="http://www.ncbi.nlm.nih.gov/pubmed/28968169">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2451 href="https://doi.org/10.1200/JCO.2017.74.4144">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2455 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5692725">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731602701">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d1627e2468 class=n-a></a>Okouneva T, Azarenko O, Wilson L, <i> et al.</i>: Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. <i>Mol Cancer Ther.</i> 2008; <b>7</b>(7): 2003â€“11. <a target=xrefwindow id=d1627e2479 href="http://www.ncbi.nlm.nih.gov/pubmed/18645010">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2482 href="https://doi.org/10.1158/1535-7163.MCT-08-0095">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2486 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2562299">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d1627e2495 class=n-a></a>Jordan MA, Kamath K, Manna T, <i> et al.</i>: The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. <i>Mol Cancer Ther.</i> 2005; <b>4</b>(7): 1086â€“95. <a target=xrefwindow id=d1627e2506 href="http://www.ncbi.nlm.nih.gov/pubmed/16020666">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2509 href="https://doi.org/10.1158/1535-7163.MCT-04-0345">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d1627e2518 class=n-a></a>Towle MJ, Salvato KA, Budrow J, <i> et al.</i>: <i>In vitro</i> and <i>in vivo</i> anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. <i>Cancer Res.</i> 2001; <b>61</b>(3): 1013â€“21. <a target=xrefwindow id=d1627e2536 href="http://www.ncbi.nlm.nih.gov/pubmed/11221827">PubMed Abstract </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d1627e2545 class=n-a></a>Kuznetsov G, Towle MJ, Cheng H, <i> et al.</i>: Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. <i>Cancer Res.</i> 2004; <b>64</b>(16): 5760â€“6. <a target=xrefwindow id=d1627e2556 href="http://www.ncbi.nlm.nih.gov/pubmed/15313917">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2559 href="https://doi.org/10.1158/0008-5472.CAN-04-1169">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735015893"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2569 class=n-a></a>WeiÃŸ LM, Hugle M, Fulda S: Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. <i>Oncotarget.</i> 2017; <b>8</b>(32): 52445â€“52456. <a target=xrefwindow id=d1627e2577 href="http://www.ncbi.nlm.nih.gov/pubmed/28881742">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2580 href="https://doi.org/10.18632/oncotarget.17190">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2583 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5581041">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735015893">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d1627e2596 class=n-a></a>Kolb EA, Gorlick R, Reynolds CP, <i> et al.</i>: Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. <i>Pediatr Blood Cancer.</i> 2013; <b>60</b>(8): 1325â€“32. <a target=xrefwindow id=d1627e2607 href="http://www.ncbi.nlm.nih.gov/pubmed/23553917">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2610 href="https://doi.org/10.1002/pbc.24517">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2614 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4263960">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732706461"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2623 class=n-a></a>Koliou P, Karavasilis V, Theochari M, <i> et al.</i>: Advances in the treatment of soft tissue sarcoma: focus on eribulin. <i>Cancer Manag Res.</i> 2018; <b>10</b>: 207â€“16. <a target=xrefwindow id=d1627e2634 href="http://www.ncbi.nlm.nih.gov/pubmed/29440930">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2637 href="https://doi.org/10.2147/CMAR.S143019">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2641 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5798537">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732706461">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733160448"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2654 class=n-a></a>Schafer ES, Rau RE, Berg S, <i> et al.</i>: A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). <i>Pediatr Blood Cancer.</i> 2018; <b>65</b>(8): e27066. <a target=xrefwindow id=d1627e2665 href="http://www.ncbi.nlm.nih.gov/pubmed/29719113">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2668 href="https://doi.org/10.1002/pbc.27066">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2672 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6019176">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733160448">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d1627e2685 class=n-a></a>NCT03441360 Eisai Inc.: A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS). In: ClinicalTrials.gov. (cited 2019, Jan 29). <a target=xrefwindow id=d1627e2687 href="https://www.clinicaltrials.gov/ct2/show/NCT03441360?term=NCT03441360&amp;rank=1">Reference Source</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d1627e2696 class=n-a></a>NCT03245450 Eisai Inc.: A Phase 1/2 Single-arm Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan in Children With Refractory or Recurrent Solid Tumors. In: ClinicalTrials.gov. (cited 2019, Jan 29). <a target=xrefwindow id=d1627e2698 href="https://www.clinicaltrials.gov/ct2/show/NCT03245450?term=NCT03245450&amp;rank=1">Reference Source</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d1627e2708 class=n-a></a>Pappo AS, Lyden E, Breitfeld P, <i> et al.</i>: Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. <i>J Clin Oncol.</i> 2007; <b>25</b>(4): 362â€“9. <a target=xrefwindow id=d1627e2719 href="http://www.ncbi.nlm.nih.gov/pubmed/17264331">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2722 href="https://doi.org/10.1200/JCO.2006.07.1720">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d1627e2731 class=n-a></a>Thompson J, George EO, Poquette CA, <i> et al.</i>: Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. <i>Clin Cancer Res.</i> 1999; <b>5</b>(11): 3617â€“31. <a target=xrefwindow id=d1627e2742 href="http://www.ncbi.nlm.nih.gov/pubmed/10589779">PubMed Abstract </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d1627e2751 class=n-a></a>Martinez C, Hofmann TJ, Marino R, <i> et al.</i>: Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. <i>Blood.</i> 2007; <b>109</b>(10): 4245â€“8. <a target=xrefwindow id=d1627e2762 href="http://www.ncbi.nlm.nih.gov/pubmed/17264296">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2765 href="https://doi.org/10.1182/blood-2006-08-039347">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2769 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1885494">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d1627e2778 class=n-a></a>Hu-Lieskovan S, Zhang J, Wu L, <i> et al.</i>: EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. <i>Cancer Res.</i> 2005; <b>65</b>(11): 4633â€“44. <a target=xrefwindow id=d1627e2789 href="http://www.ncbi.nlm.nih.gov/pubmed/15930281">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2792 href="https://doi.org/10.1158/0008-5472.CAN-04-2857">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d1627e2801 class=n-a></a>von Levetzow C, Jiang X, Gwye Y, <i> et al.</i>: Modeling initiation of Ewing sarcoma in human neural crest cells. <i>PLoS One.</i> 2011; <b>6</b>(4): e19305. <a target=xrefwindow id=d1627e2812 href="http://www.ncbi.nlm.nih.gov/pubmed/21559395">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2815 href="https://doi.org/10.1371/journal.pone.0019305">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2819 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3084816">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1108778"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2828 class=n-a></a>Tirode F, Laud-Duval K, Prieur A, <i> et al.</i>: Mesenchymal stem cell features of Ewing tumors. <i>Cancer Cell.</i> 2007; <b>11</b>(5): 421â€“9. <a target=xrefwindow id=d1627e2839 href="http://www.ncbi.nlm.nih.gov/pubmed/17482132">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2842 href="https://doi.org/10.1016/j.ccr.2007.02.027">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1108778">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726423951"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2856 class=n-a></a>Dobrenkov K, Ostrovnaya I, Gu J, <i> et al.</i>: Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. <i>Pediatr Blood Cancer.</i> 2016; <b>63</b>(10): 1780â€“5. <a target=xrefwindow id=d1627e2867 href="http://www.ncbi.nlm.nih.gov/pubmed/27304202">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2870 href="https://doi.org/10.1002/pbc.26097">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2874 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5215083">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726423951">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d1627e2887 class=n-a></a>Kailayangiri S, Altvater B, Meltzer J, <i> et al.</i>: The ganglioside antigen G<sub>D2</sub> is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. <i>Br J Cancer.</i> 2012; <b>106</b>(6): 1123â€“33. <a target=xrefwindow id=d1627e2901 href="http://www.ncbi.nlm.nih.gov/pubmed/22374462">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2905 href="https://doi.org/10.1038/bjc.2012.57">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2908 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3304425">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726192020"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e2917 class=n-a></a>Fisher JP, Flutter B, Wesemann F, <i> et al.</i>: Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with VÎ³9VÎ´2+ Î³Î´T cells. <i>Oncoimmunology.</i> 2016; <b>5</b>(1): e1025194. <a target=xrefwindow id=d1627e2928 href="http://www.ncbi.nlm.nih.gov/pubmed/26942051">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2931 href="https://doi.org/10.1080/2162402X.2015.1025194">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2935 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4760299">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726192020">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d1627e2948 class=n-a></a>Lipinski M, Hirsch MR, Deagostini-Bazin H, <i> et al.</i>: Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines. <i>Int J Cancer.</i> 1987; <b>40</b>(1): 81â€“6. <a target=xrefwindow id=d1627e2959 href="http://www.ncbi.nlm.nih.gov/pubmed/3036723">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2962 href="https://doi.org/10.1002/ijc.2910400115">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d1627e2971 class=n-a></a>Mody R, Naranjo A, Van Ryn C, <i> et al.</i>: Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. <i>Lancet Oncol.</i> 2017; <b>18</b>(7): 946â€“57. <a target=xrefwindow id=d1627e2982 href="http://www.ncbi.nlm.nih.gov/pubmed/28549783">PubMed Abstract </a> | <a target=xrefwindow id=d1627e2985 href="https://doi.org/10.1016/S1470-2045(17)30355-8">Publisher Full Text </a> | <a target=xrefwindow id=d1627e2989 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5527694">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d1627e2998 class=n-a></a>DuBois SG, Marina N, Glade-Bender J: Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. <i>Cancer.</i> 2010; <b>116</b>(3): 749â€“57. <a target=xrefwindow id=d1627e3006 href="http://www.ncbi.nlm.nih.gov/pubmed/20029966">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3009 href="https://doi.org/10.1002/cncr.24844">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3012 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2815027">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d1627e3022 class=n-a></a>Zhou Z, Bolontrade MF, Reddy K, <i> et al.</i>: Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. <i>Clin Cancer Res.</i> 2007; <b>13</b>(16): 4867â€“73. <a target=xrefwindow id=d1627e3033 href="http://www.ncbi.nlm.nih.gov/pubmed/17699866">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3036 href="https://doi.org/10.1158/1078-0432.CCR-07-0133">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d1627e3045 class=n-a></a>Reddy K, Zhou Z, Schadler K, <i> et al.</i>: Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. <i>Mol Cancer Res.</i> 2008; <b>6</b>(6): 929â€“36. <a target=xrefwindow id=d1627e3056 href="http://www.ncbi.nlm.nih.gov/pubmed/18567797">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3059 href="https://doi.org/10.1158/1541-7786.MCR-07-2189">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3063 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2441901">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d1627e3072 class=n-a></a>Potikyan G, Savene RO, Gaulden JM, <i> et al.</i>: EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. <i>Cancer Res.</i> 2007; <b>67</b>(14): 6675â€“84. <a target=xrefwindow id=d1627e3083 href="http://www.ncbi.nlm.nih.gov/pubmed/17638877">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3086 href="https://doi.org/10.1158/0008-5472.CAN-06-4140">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d1627e3095 class=n-a></a>Fleuren ED, Versleijen-Jonkers YM, Boerman OC, <i> et al.</i>: Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives. <i>Biochim Biophys Acta.</i> 2014; <b>1845</b>(2): 266â€“76. <a target=xrefwindow id=d1627e3106 href="http://www.ncbi.nlm.nih.gov/pubmed/24582852">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3109 href="https://doi.org/10.1016/j.bbcan.2014.02.005">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d1627e3118 class=n-a></a>Bukowski RM, Yasothan U, Kirkpatrick P: Pazopanib. <i>Nat Rev Drug Discov.</i> 2010; <b>9</b>(1): 17â€“8. <a target=xrefwindow id=d1627e3126 href="http://www.ncbi.nlm.nih.gov/pubmed/20043026">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3129 href="https://doi.org/10.1038/nrd3073">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/719895110"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e3138 class=n-a></a>van der Graaf WT, Blay JY, Chawla SP, <i> et al.</i>: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet.</i> 2012; <b>379</b>(9829): 1879â€“86. <a target=xrefwindow id=d1627e3149 href="http://www.ncbi.nlm.nih.gov/pubmed/22595799">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3152 href="https://doi.org/10.1016/S0140-6736(12)60651-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/719895110">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d1627e3166 class=n-a></a>Keir ST, Morton CL, Wu J, <i> et al.</i>: Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. <i>Pediatr Blood Cancer.</i> 2012; <b>59</b>(3): 586â€“8. <a target=xrefwindow id=d1627e3177 href="http://www.ncbi.nlm.nih.gov/pubmed/22190407">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3180 href="https://doi.org/10.1002/pbc.24016">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3184 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4245051">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d1627e3193 class=n-a></a>Alcindor T: Response of refractory Ewing sarcoma to pazopanib. <i>Acta Oncol.</i> 2015; <b>54</b>(7): 1063â€“4. <a target=xrefwindow id=d1627e3201 href="http://www.ncbi.nlm.nih.gov/pubmed/25345493">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3204 href="https://doi.org/10.3109/0284186X.2014.971938">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730008326"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e3213 class=n-a></a>Attia S, Okuno SH, Robinson SI, <i> et al.</i>: Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. <i>Rare Tumors.</i> 2017; <b>7</b>(2): 86â€“8. <a target=xrefwindow id=d1627e3224 href="http://www.ncbi.nlm.nih.gov/pubmed/26266019">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3227 href="https://doi.org/10.4081/rt.2015.5992">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3231 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4508650">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730008326">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d1627e3244 class=n-a></a>Yamamoto Y, Nozawa M, Shimizu N, <i> et al.</i>: Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum. <i>Int J Urol.</i> 2014; <b>21</b>(11): 1183â€“4. <a target=xrefwindow id=d1627e3255 href="http://www.ncbi.nlm.nih.gov/pubmed/25040171">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3258 href="https://doi.org/10.1111/iju.12546">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d1627e3267 class=n-a></a>Italiano A, Penel N, Toulmonde M, <i> et al.</i>: Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/US National Cancer Institute phase II collaborative study. <i>Connective Tissue Oncology Society Annual Meeting</i>. Rome, Italy 2018. <a target=xrefwindow id=d1627e3275 href="https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Cabozantinib-in-Patients-With-Advanced-Osteosarcomas-and-Ewing-sarcomas-a-French-Sarcoma-Group-FSG-US-National-Cancer-Institute-phase-II-collaborative-study">Reference Source</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733109543"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e3284 class=n-a></a>Chuk MK, Widemann BC, Minard CG, <i> et al.</i>: A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. <i>Pediatr Blood Cancer.</i> 2018; <b>65</b>(8): e27077. <a target=xrefwindow id=d1627e3295 href="http://www.ncbi.nlm.nih.gov/pubmed/29693796">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3298 href="https://doi.org/10.1002/pbc.27077">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3302 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6082380">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733109543">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718036740"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e3316 class=n-a></a>Glade Bender JL, Lee A, Reid JM, <i> et al.</i>: Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. <i>J Clin Oncol.</i> 2013; <b>31</b>(24): 3034â€“43. <a target=xrefwindow id=d1627e3327 href="http://www.ncbi.nlm.nih.gov/pubmed/23857966">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3330 href="https://doi.org/10.1200/JCO.2012.47.0914">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3334 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3739862">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718036740">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d1627e3347 class=n-a></a>Attia S, Bolejack V, Ganjoo KN, <i> et al.</i>: A phase 2 trial of regorafenib (REGO) in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC0024 trial results. <i>J Clin Oncol.</i> 2017; <b>35</b>(15 suppl): abstr 11005. <a target=xrefwindow id=d1627e3358 href="https://doi.org/10.1200/JCO.2017.35.15_suppl.11005">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d1627e3367 class=n-a></a>Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. <i>Nature.</i> 1993; <b>366</b>(6456): 704â€“7. <a target=xrefwindow id=d1627e3375 href="http://www.ncbi.nlm.nih.gov/pubmed/8259215">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3378 href="https://doi.org/10.1038/366704a0">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d1627e3387 class=n-a></a>Huang HY, Illei PB, Zhao Z, <i> et al.</i>: Ewing sarcomas with <i>p53</i> mutation or <i>p16/p14ARF</i> homozygous deletion: a highly lethal subset associated with poor chemoresponse. <i>J Clin Oncol.</i> 2005; <b>23</b>(3): 548â€“58. <a target=xrefwindow id=d1627e3405 href="http://www.ncbi.nlm.nih.gov/pubmed/15659501">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3408 href="https://doi.org/10.1200/JCO.2005.02.081">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718486848"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e3417 class=n-a></a>Brohl AS, Solomon DA, Chang W, <i> et al.</i>: The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent <i>STAG2</i> mutation. <i>PLoS Genet.</i> 2014; <b>10</b>(7): e1004475. <a target=xrefwindow id=d1627e3431 href="http://www.ncbi.nlm.nih.gov/pubmed/25010205">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3435 href="https://doi.org/10.1371/journal.pgen.1004475">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3438 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4091782">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718486848">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718632867"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e3451 class=n-a></a>Crompton BD, Stewart C, Taylor-Weiner A, <i> et al.</i>: The genomic landscape of pediatric Ewing sarcoma. <i>Cancer Discov.</i> 2014; <b>4</b>(11): 1326â€“41. <a target=xrefwindow id=d1627e3462 href="http://www.ncbi.nlm.nih.gov/pubmed/25186949">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3465 href="https://doi.org/10.1158/2159-8290.CD-13-1037">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718632867">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d1627e3479 class=n-a></a>Lerman DM, Monument MJ, McIlvaine E, <i> et al.</i>: Tumoral <i>TP53</i> and/or <i>CDKN2A</i> alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. <i>Pediatr Blood Cancer.</i> 2015; <b>62</b>(5): 759â€“65. <a target=xrefwindow id=d1627e3497 href="http://www.ncbi.nlm.nih.gov/pubmed/25464386">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3500 href="https://doi.org/10.1002/pbc.25340">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3503 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4376595">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d1627e3512 class=n-a></a>Kennedy AL, Vallurupalli M, Chen L, <i> et al.</i>: Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. <i>Oncotarget.</i> 2015; <b>6</b>(30): 30178â€“93. <a target=xrefwindow id=d1627e3523 href="http://www.ncbi.nlm.nih.gov/pubmed/26337082">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3526 href="https://doi.org/10.18632/oncotarget.4903">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3530 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4745789">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d1627e3539 class=n-a></a>Dowless M, Lowery CD, Shackleford T, <i> et al.</i>: Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling. <i>Clin Cancer Res.</i> 2018; <b>24</b>(23): 6028â€“39. <a target=xrefwindow id=d1627e3550 href="http://www.ncbi.nlm.nih.gov/pubmed/30131386">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3553 href="https://doi.org/10.1158/1078-0432.CCR-18-1256">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3557 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6279561">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d1627e3566 class=n-a></a>NCT02644460: Cynthia Wetmore, Emory University, Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors. In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e3568 href="https://www.clinicaltrials.gov/ct2/show/NCT02644460?term=NCT02644460&amp;rank=1">Reference Source</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d1627e3577 class=n-a></a>NCT01747876: Novartis Pharmaceuticals, A Phase I, Multi-center, Open-label Study of LEE011 in Patients With Malignant Rhabdoid Tumors and Neuroblastoma. In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e3579 href="https://www.clinicaltrials.gov/ct2/show/NCT01747876?term=NCT01747876&amp;rank=1">Reference Source</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d1627e3588 class=n-a></a>NCT02255461: Pediatric Brain Tumor Consortium, Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central NervousSystem Tumors. In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e3590 href="https://www.clinicaltrials.gov/ct2/show/NCT02255461?term=NCT02255461&amp;rank=1">Reference Source</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d1627e3600 class=n-a></a>Geoerger B, Bourdeaut F, DuBois SG, <i> et al.</i>: A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. <i>Clin Cancer Res.</i> 2017; <b>23</b>(10): 2433â€“41. <a target=xrefwindow id=d1627e3611 href="http://www.ncbi.nlm.nih.gov/pubmed/28432176">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3614 href="https://doi.org/10.1158/1078-0432.CCR-16-2898">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d1627e3623 class=n-a></a>McClendon AK, Dean JL, Rivadeneira DB, <i> et al.</i>: CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. <i>Cell Cycle.</i> 2012; <b>11</b>(14): 2747â€“55. <a target=xrefwindow id=d1627e3634 href="http://www.ncbi.nlm.nih.gov/pubmed/22751436">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3637 href="https://doi.org/10.4161/cc.21127">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3641 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3409014">Free Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d1627e3650 class=n-a></a>NCT03709680: Pfizer, Phase 1 study to evaluate the safety and pharmacokinetics of palbociclib in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory solid tumors. In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e3652 href="https://www.clinicaltrials.gov/ct2/show/NCT03709680?term=NCT03709680&amp;rank=1">Reference Source</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d1627e3661 class=n-a></a>NCT03387020: Pediatric Brain Tumor Consortium, A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors. In: ClinicalTrials.gov (cited 2019, Jan 29), <a target=xrefwindow id=d1627e3663 href="https://www.clinicaltrials.gov/ct2/show/NCT03387020?term=NCT03387020&amp;rank=1">Reference Source</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d1627e3672 class=n-a></a>NCT03114527: Fox Chase Cancer Center, Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS). In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e3674 href="https://www.clinicaltrials.gov/ct2/show/NCT03114527?term=NCT03114527&amp;rank=1">Reference Source</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d1627e3683 class=n-a></a>NCT02703571: Novartis Pharmaceuticals, A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors. In: ClinicalTrials.gov (cited 2019,Jan 29). <a target=xrefwindow id=d1627e3685 href="https://www.clinicaltrials.gov/ct2/show/NCT02703571?term=NCT02703571&amp;rank=1">Reference Source</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d1627e3695 class=n-a></a>Guenther LM, Dharia NV, Ross L, <i> et al.</i>: A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. <i>Clin Cancer Res.</i> 2019; <b>25</b>(4): 1343â€“57. <a target=xrefwindow id=d1627e3706 href="http://www.ncbi.nlm.nih.gov/pubmed/30397176">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3709 href="https://doi.org/10.1158/1078-0432.CCR-18-0372">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/719411014"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e3718 class=n-a></a>Brenner JC, Feng FY, Han S, <i> et al.</i>: PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. <i>Cancer Res.</i> 2012; <b>72</b>(7): 1608â€“13. <a target=xrefwindow id=d1627e3729 href="http://www.ncbi.nlm.nih.gov/pubmed/22287547">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3732 href="https://doi.org/10.1158/0008-5472.CAN-11-3648">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3736 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3319786">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/719411014">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14267128"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e3749 class=n-a></a>Garnett MJ, Edelman EJ, Heidorn SJ, <i> et al.</i>: Systematic identification of genomic markers of drug sensitivity in cancer cells. <i>Nature.</i> 2012; <b>483</b>(7391): 570â€“5. <a target=xrefwindow id=d1627e3760 href="http://www.ncbi.nlm.nih.gov/pubmed/22460902">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3763 href="https://doi.org/10.1038/nature11005">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3767 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3349233">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14267128">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732611663"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e3780 class=n-a></a>Vormoor B, Schlosser YT, Blair H, <i> et al.</i>: Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2. <i>Oncotarget.</i> 2017; <b>8</b>(69): 113418â€“30. <a target=xrefwindow id=d1627e3791 href="http://www.ncbi.nlm.nih.gov/pubmed/29371919">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3794 href="https://doi.org/10.18632/oncotarget.21300">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3798 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5768336">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732611663">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726637195"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e3811 class=n-a></a>Stewart E, Goshorn R, Bradley C, <i> et al.</i>: Targeting the DNA repair pathway in Ewing sarcoma. <i>Cell Rep.</i> 2014; <b>9</b>(3): 829â€“41. <a target=xrefwindow id=d1627e3822 href="http://www.ncbi.nlm.nih.gov/pubmed/25437539">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3825 href="https://doi.org/10.1016/j.celrep.2014.09.028">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3829 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4386669">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726637195">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725276920"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e3842 class=n-a></a>Smith MA, Reynolds CP, Kang MH, <i> et al.</i>: Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. <i>Clin Cancer Res.</i> 2015; <b>21</b>(4): 819â€“32. <a target=xrefwindow id=d1627e3853 href="http://www.ncbi.nlm.nih.gov/pubmed/25500058">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3856 href="https://doi.org/10.1158/1078-0432.CCR-14-2572">Publisher Full Text </a> | <a target=xrefwindow id=d1627e3860 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4587665">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725276920">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d1627e3874 class=n-a></a>NCT02392793. St. Jude Children's Research Hospital: A Phase I Study of Talazoparib (BMN 673) Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies. In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e3876 href="https://www.clinicaltrials.gov/ct2/show/NCT02392793?term=NCT02392793&amp;rank=1">Reference Source</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d1627e3885 class=n-a></a>NCT02116777. National Cancer Institute: A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies. In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e3887 href="https://www.clinicaltrials.gov/ct2/show/NCT02116777?term=NCT02116777&amp;rank=1">Reference Source</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d1627e3896 class=n-a></a>NCT01858168. Edwin Choy, MD Massachusetts General Hospital: Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy. In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e3898 href="https://www.clinicaltrials.gov/ct2/show/NCT01858168?term=NCT01858168&amp;rank=1">Reference Source</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d1627e3907 class=n-a></a>NCT02044120. Sarcoma Alliance for Research through Collaboration: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan in Patients With Previously Treated,Incurable Ewing Sarcoma. In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e3909 href="https://www.clinicaltrials.gov/ct2/show/NCT02044120?term=NCT02044120&amp;rank=1">Reference Source</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d1627e3918 class=n-a></a>Federico S, Stewart E, Coleman J, <i> et al.</i>: Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors. <i>J Clin Oncol.</i> 2017; <b>35</b>(15_suppl): 10542. <a target=xrefwindow id=d1627e3929 href="https://doi.org/10.1200/JCO.2017.35.15_suppl.10542">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d1627e3938 class=n-a></a>Saylors RL 3rd, Stine KC, Sullivan J, <i> et al.</i>: Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. <i>J Clin Oncol.</i> 2001; <b>19</b>(15): 3463â€“9. <a target=xrefwindow id=d1627e3949 href="http://www.ncbi.nlm.nih.gov/pubmed/11481351">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3952 href="https://doi.org/10.1200/JCO.2001.19.15.3463">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d1627e3962 class=n-a></a>Hunold A, Weddeling N, Paulussen M, <i> et al.</i>: Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. <i>Pediatr Blood Cancer.</i> 2006; <b>47</b>(6): 795â€“800. <a target=xrefwindow id=d1627e3973 href="http://www.ncbi.nlm.nih.gov/pubmed/16411206">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3976 href="https://doi.org/10.1002/pbc.20719">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d1627e3985 class=n-a></a>Bernstein ML, Devidas M, Lafreniere D, <i> et al.</i>: Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. <i>J Clin Oncol.</i> 2006; <b>24</b>(1): 152â€“9. <a target=xrefwindow id=d1627e3996 href="http://www.ncbi.nlm.nih.gov/pubmed/16382125">PubMed Abstract </a> | <a target=xrefwindow id=d1627e3999 href="https://doi.org/10.1200/JCO.2005.02.1717">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d1627e4008 class=n-a></a>Farhat R, Raad R, Khoury NJ, <i> et al.</i>: Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution. <i>J Pediatr Hematol Oncol.</i> 2013; <b>35</b>(5): 356â€“60. <a target=xrefwindow id=d1627e4019 href="http://www.ncbi.nlm.nih.gov/pubmed/23042020">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4022 href="https://doi.org/10.1097/MPH.0b013e318270a343">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d1627e4031 class=n-a></a>Kebudi R, Cakir FB, Gorgun O, <i> et al.</i>: A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors. <i>Pediatr Hematol Oncol.</i> 2013; <b>30</b>(3): 170â€“7. <a target=xrefwindow id=d1627e4042 href="http://www.ncbi.nlm.nih.gov/pubmed/23484903">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4045 href="https://doi.org/10.3109/08880018.2013.767868">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d1627e4054 class=n-a></a>Wagner L: Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions. <i>Sarcoma.</i> 2011; <b>2011</b>: 957957. <a target=xrefwindow id=d1627e4062 href="http://www.ncbi.nlm.nih.gov/pubmed/21512587">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4065 href="https://doi.org/10.1155/2011/957957">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4068 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3075817">Free Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d1627e4077 class=n-a></a>Mascarenhas L, Felgenhauer JL, Bond MC, <i> et al.</i>: Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. <i>Pediatr Blood Cancer.</i> 2016; <b>63</b>(3): 493â€“8. <a target=xrefwindow id=d1627e4088 href="http://www.ncbi.nlm.nih.gov/pubmed/26579879">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4091 href="https://doi.org/10.1002/pbc.25837">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4095 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4860347">Free Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1165260"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e4105 class=n-a></a>Casey DA, Wexler LH, Merchant MS, <i> et al.</i>: Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. <i>Pediatr Blood Cancer.</i> 2009; <b>53</b>(6): 1029â€“34. <a target=xrefwindow id=d1627e4116 href="http://www.ncbi.nlm.nih.gov/pubmed/19637327">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4119 href="https://doi.org/10.1002/pbc.22206">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1165260">F1000 Recommendation</a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d1627e4132 class=n-a></a>Wagner LM, McAllister N, Goldsby RE, <i> et al.</i>: Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. <i>Pediatr Blood Cancer.</i> 2007; <b>48</b>(2): 132â€“9. <a target=xrefwindow id=d1627e4143 href="http://www.ncbi.nlm.nih.gov/pubmed/16317751">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4146 href="https://doi.org/10.1002/pbc.20697">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d1627e4155 class=n-a></a>Wagner LM: Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? <i>Clin Sarcoma Res.</i> 2015; <b>5</b>: 20. <a target=xrefwindow id=d1627e4163 href="http://www.ncbi.nlm.nih.gov/pubmed/26322224">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4166 href="https://doi.org/10.1186/s13569-015-0035-x">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4169 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4552408">Free Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733242040"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e4178 class=n-a></a>Palmerini E, Jones RL, Setola E, <i> et al.</i>: Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. <i>Acta Oncol.</i> 2018; <b>57</b>(7): 958â€“64. <a target=xrefwindow id=d1627e4189 href="http://www.ncbi.nlm.nih.gov/pubmed/29533113">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4192 href="https://doi.org/10.1080/0284186X.2018.1449250">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733242040">F1000 Recommendation</a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d1627e4205 class=n-a></a>Houghton PJ, Stewart CF, Cheshire PJ, <i> et al.</i>: Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. <i>Clin Cancer Res.</i> 2000; <b>6</b>(10): 4110â€“8. <a target=xrefwindow id=d1627e4216 href="http://www.ncbi.nlm.nih.gov/pubmed/11051264">PubMed Abstract </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d1627e4225 class=n-a></a>Patel VJ, Elion GB, Houghton PJ, <i> et al.</i>: Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. <i>Clin Cancer Res.</i> 2000; <b>6</b>(10): 4154â€“7. <a target=xrefwindow id=d1627e4236 href="http://www.ncbi.nlm.nih.gov/pubmed/11051270">PubMed Abstract </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d1627e4246 class=n-a></a>Furman WL, Crews KR, Billups C, <i> et al.</i>: Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. <i>J Clin Oncol.</i> 2006; <b>24</b>(4): 563â€“70. <a target=xrefwindow id=d1627e4257 href="http://www.ncbi.nlm.nih.gov/pubmed/16446328">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4260 href="https://doi.org/10.1200/JCO.2005.03.2847">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d1627e4269 class=n-a></a>McGregor LM, Stewart CF, Crews KR, <i> et al.</i>: Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. <i>Pediatr Blood Cancer.</i> 2012; <b>58</b>(3): 372â€“9. <a target=xrefwindow id=d1627e4280 href="http://www.ncbi.nlm.nih.gov/pubmed/21509928">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4283 href="https://doi.org/10.1002/pbc.23075">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4287 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3256281">Free Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d1627e4296 class=n-a></a>Newlands ES, Blackledge GR, Slack JA, <i> et al.</i>: Phase I trial of temozolomide (CCRG 81045: M&amp;B 39831: NSC 362856). <i>Br J Cancer.</i> 1992; <b>65</b>(2): 287â€“91. <a target=xrefwindow id=d1627e4307 href="http://www.ncbi.nlm.nih.gov/pubmed/1739631">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4310 href="https://doi.org/10.1038/bjc.1992.57">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4314 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1977719">Free Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d1627e4323 class=n-a></a>Nicholson HS, Krailo M, Ames MM, <i> et al.</i>: Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. <i>J Clin Oncol.</i> 1998; <b>16</b>(9): 3037â€“43. <a target=xrefwindow id=d1627e4334 href="http://www.ncbi.nlm.nih.gov/pubmed/9738573">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4337 href="https://doi.org/10.1200/JCO.1998.16.9.3037">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d1627e4346 class=n-a></a>Estlin EJ, Lashford L, Ablett S, <i> et al.</i>: Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. <i>Br J Cancer.</i> 1998; <b>78</b>(5): 652â€“61. <a target=xrefwindow id=d1627e4357 href="http://www.ncbi.nlm.nih.gov/pubmed/9744506">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4360 href="https://doi.org/10.1038/bjc.1998.555">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4364 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2063055">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d1627e4373 class=n-a></a>DuBois SG, Mosse YP, Fox E, <i> et al.</i>: Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. <i>Clin Cancer Res.</i> 2018; <b>24</b>(24): 6142â€“9. <a target=xrefwindow id=d1627e4384 href="http://www.ncbi.nlm.nih.gov/pubmed/30093449">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4387 href="https://doi.org/10.1158/1078-0432.CCR-18-1381">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4391 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6295246">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d1627e4401 class=n-a></a>Bagatell R, Norris R, Ingle AM, <i> et al.</i>: Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. <i>Pediatr Blood Cancer.</i> 2014; <b>61</b>(5): 833â€“9. <a target=xrefwindow id=d1627e4412 href="http://www.ncbi.nlm.nih.gov/pubmed/24249672">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4415 href="https://doi.org/10.1002/pbc.24874">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4419 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4196713">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d1627e4428 class=n-a></a>NCT03495921. Gradalis, Inc.: A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma. In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e4430 href="https://www.clinicaltrials.gov/ct2/show/NCT03495921?term=NCT03495921&amp;rank=1">Reference Source</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d1627e4439 class=n-a></a>Magnan H, Goodbody CM, Riedel E, <i> et al.</i>: Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. <i>Pediatr Blood Cancer.</i> 2015; <b>62</b>(4): 594â€“7. <a target=xrefwindow id=d1627e4450 href="http://www.ncbi.nlm.nih.gov/pubmed/25630954">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4453 href="https://doi.org/10.1002/pbc.25373">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4457 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4474186">Free Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d1627e4466 class=n-a></a>Miser JS, Krailo MD, Tarbell NJ, <i> et al.</i>: Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. <i>J Clin Oncol.</i> 2004; <b>22</b>(14): 2873â€“6. <a target=xrefwindow id=d1627e4477 href="http://www.ncbi.nlm.nih.gov/pubmed/15254055">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4480 href="https://doi.org/10.1200/JCO.2004.01.041">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d1627e4489 class=n-a></a>NCT01864109. Memorial Sloan Kettering Cancer Center: A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma. In: ClinicalTrials.gov (cited 2019, Jan 29). <a target=xrefwindow id=d1627e4491 href="https://www.clinicaltrials.gov/ct2/show/NCT01864109?term=NCT01864109&amp;rank=1">Reference Source</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d1627e4500 class=n-a></a>Bielack SS, Smeland S, Whelan JS, <i> et al.</i>: Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. <i>J Clin Oncol.</i> 2015; <b>33</b>(20): 2279â€“87. <a target=xrefwindow id=d1627e4511 href="http://www.ncbi.nlm.nih.gov/pubmed/26033801">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4514 href="https://doi.org/10.1200/JCO.2014.60.0734">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4518 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4486345">Free Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d1627e4528 class=n-a></a>Sankar S, Bell R, Stephens B, <i> et al.</i>: Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. <i>Oncogene.</i> 2013; <b>32</b>(47): 5089â€“100. <a target=xrefwindow id=d1627e4539 href="http://www.ncbi.nlm.nih.gov/pubmed/23178492">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4542 href="https://doi.org/10.1038/onc.2012.525">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4546 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3899696">Free Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732542772"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1627e4555 class=n-a></a>Iniguez AB, Stolte B, Wang EJ, <i> et al.</i>: EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. <i>Cancer Cell.</i> 2018; <b>33</b>(2): 202â€“216.e6. <a target=xrefwindow id=d1627e4566 href="http://www.ncbi.nlm.nih.gov/pubmed/29358035">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4569 href="https://doi.org/10.1016/j.ccell.2017.12.009">Publisher Full Text </a> | <a target=xrefwindow id=d1627e4573 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5846483">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732542772">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d1627e4586 class=n-a></a>Harlow ML, Chasse MH, Boguslawski EA, <i> et al.</i>: Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner. <i>Clin Cancer Res.</i> 2019; clincanres.3511.2018. <a target=xrefwindow id=d1627e4594 href="http://www.ncbi.nlm.nih.gov/pubmed/30723142">PubMed Abstract </a> | <a target=xrefwindow id=d1627e4597 href="https://doi.org/10.1158/1078-0432.CCR-18-3511">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 15 Apr 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-493/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-493/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Division of Pediatric Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA<br/> <sup>2</sup> Center for Cancer and Blood Disorders, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA<br/> <sup>3</sup> Departments of Pediatrics and Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA<br/> <sup>4</sup> Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA<br/> <sup>5</sup> Departement of Pediatrics, Van Andel Institute, Helen De Vos Children&rsquo;s Hospital and Michigan State University, Grand Rapids, MI, USA<br/> <sup>6</sup> Greehey Children&rsquo;s Cancer Research Institute, University of Texas Health Science Center, San Antonio, TX, USA<br/> <sup>7</sup> Center for Cancer and Blood Disorders, Connecticut Children&rsquo;s Medical Center, Hartford, CT, USA<br/> <sup>8</sup> Department of Oncology, St. Jude Children&rsquo;s Research Hospital, Memphis, TN, USA<br/> <sup>9</sup> Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA<br/> <sup>10</sup> The Faris D. Virani Ewing Sarcoma Center at the Texas Children&rsquo;s Cancer Center, Baylor College of Medicine, Houston, TX, USA<br/> <sup>11</sup> AYA Program, Moffitt Cancer Center, Tampa, FL, USA<br/> <sup>12</sup> Johns Hopkins All Children&rsquo;s Hospital, St. Petersburg, FL, USA<br/> <sup>13</sup> Dana-Farber/Boston Children&rsquo;s Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA<br/> <sup>14</sup> Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <sup>15</sup> Center for Childhood Cancer and Blood Diseases, Research Institute at Nationwide Children&rsquo;s Hospital, Columbus, OH, USA<br/> <sup>16</sup> Division of Pediatric Hematology/Oncology/Bone Marrow Transplantation, The Ohio State University College of Medicine, Columbus, OH, USA<br/> <sup>17</sup> Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA<br/> <p> <div class=margin-bottom> Kelly Bailey <br/> <span>Roles: </span> Conceptualization, Methodology, Visualization, Writing â€“ Original Draft Preparation, Writing â€“ Review & Editing </div> <div class=margin-bottom> Carrye Cost <br/> <span>Roles: </span> Conceptualization, Methodology, Visualization, Writing â€“ Original Draft Preparation, Writing â€“ Review & Editing </div> <div class=margin-bottom> Ian Davis <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Julia Glade-Bender <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Patrick Grohar <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Peter Houghton <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Michael Isakoff <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Elizabeth Stewart <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Nadia Laack <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Jason Yustein <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Damon Reed <br/> <span>Roles: </span> Methodology, Writing â€“ Review & Editing </div> <div class=margin-bottom> Katherine Janeway <br/> <span>Roles: </span> Writing â€“ Review & Editing </div> <div class=margin-bottom> Richard Gorlick <br/> <span>Roles: </span> Writing â€“ Review & Editing </div> <div class=margin-bottom> Stephen Lessnick <br/> <span>Roles: </span> Methodology, Project Administration, Supervision, Writing â€“ Review & Editing </div> <div class=margin-bottom> Steven DuBois <br/> <span>Roles: </span> Conceptualization, Methodology, Project Administration, Supervision, Visualization, Writing â€“ Review & Editing </div> <div class=margin-bottom> Pooja Hingorani <br/> <span>Roles: </span> Conceptualization, Methodology, Project Administration, Supervision, Visualization, Writing â€“ Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-493/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 15 Apr 2019, 8:493 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.18139.1">https://doi.org/10.12688/f1000research.18139.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> Â© 2019 Bailey K <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=19837 data-id=18139 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18139.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-493/v1/pdf?article_uuid=42f39dc6-b0de-4551-bddc-eb93b2f7dd29" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.18139.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Bailey K, Cost C, Davis I <em>et al.</em> Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Childrenâ€™s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force [version 1; peer review: 3 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):493 (<a href="https://doi.org/10.12688/f1000research.18139.1" target=_blank>https://doi.org/10.12688/f1000research.18139.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=18139 id=mobile-track-article-signin-18139 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18139?target=/articles/8-493/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=19837 /> <input name=articleId type=hidden value=18139 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Alan W Craft</strong>, Northern Institute for Cancer Research, Newcastle University, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Antonio Llombart-Bosch</strong>, Pathology Department, University of Valencia, Spain </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>David J Gordon</strong>, Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 15 Apr 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-493/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-493/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=49238-47019></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=49236-47021></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=49237-47020></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-493/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>15 Apr 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Alan W Craft</strong>, Northern Institute for Cancer Research, Newcastle University, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Antonio Llombart-Bosch</strong>, Pathology Department, University of Valencia, Spain </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>David J Gordon</strong>, Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-493/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-493/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Emerging novel agents for patients with advanced...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-493/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-493/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-493/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Bailey K et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-493/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-493",
            templates : {
                twitter : "Emerging novel agents for patients with advanced Ewing sarcoma:.... Bailey K et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-493/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children\u2019s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children\u2019s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/18139/19837")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "19837");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "47019": 0,
                           "47020": 0,
                           "47021": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "a4339126-5789-42c0-a2bf-5cb65b4b245e";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-493.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-493.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-493.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-493.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-493.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>